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PPAR target genes <p>A combined experimental and <it>in silico </it>approach identifies Peroxisome Proliferator Activated Receptor (PPAR) binding sites  and six novel target genes in the human genome.</p>
Abstract
Background: Peroxisome proliferator-activated receptors (PPARs) are known for their critical
role in the development of diseases, such as obesity, cardiovascular disease, type 2 diabetes and
cancer. Here, an in silico screening method is presented, which incorporates experiment- and
informatics-derived evidence, such as DNA-binding data of PPAR subtypes to a panel of PPAR
response elements (PPREs), PPRE location relative to the transcription start site (TSS) and PPRE
conservation across multiple species, for more reliable prediction of PPREs.
Results: In vitro binding and in vivo functionality evidence agrees with in silico predictions, validating
the approach. The experimental analysis of 30 putative PPREs in eight validated PPAR target genes
indicates that each gene contains at least one functional, strong PPRE that occurs without positional
bias relative to the TSS. An extended analysis of the cross-species conservation of PPREs reveals
limited conservation of PPRE patterns, although PPAR target genes typically contain strong or
multiple medium strength PPREs. Human chromosome 19 was screened using this method, with
validation of six novel PPAR target genes.
Conclusion: An in silico screening approach is presented, which allows increased sensitivity of
PPAR binding site and target gene detection.
Background
Lipid level dys-regulation is a characteristic common to some
of the most prevalent medical disorders, including obesity,
cardiovascular disease and type 2 diabetes [1]. Nuclear recep-
tors (NRs) are transcription factors that have important roles
in these diseases, because many of them have lipophilic com-
pounds as ligands, including cholesterol, fatty acids and their
metabolic derivatives [2]. For example, native and oxidized
polyunsaturated fatty acids as well as arachidonic acid deriv-
atives, such as prostaglandins and prostacyclins, selectively
bind the NRs peroxisome proliferator-activated receptor
(PPAR)α, PPARγ and PPARβ/δ and stimulate their ability to
activate target genes transcriptionally [3]. The PPAR tran-
scription factors are prominent players in the metabolic syn-
drome, because of their role as important regulators of lipid
storage and catabolism [4]. However, they also regulate cellu-
lar growth and differentiation and, therefore, have an impact
on hyper-proliferative diseases, such as cancer [5]. Known
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primary PPAR targets may be incompletely characterized for
their regulatory regions involved in their regulation by
PPARs. In rodents a large number of significantly inducible
PPAR target genes have been identified [6,7], while in human
cell lines only a few genes are activated more than two-fold by
PPAR ligands [8]. In parallel, PPARs have a relatively high
basal activity [9]. These facts suggest that there is a need to
identify new PPAR response elements (PPREs) and target
genes in an unbiased way that is independent of ligand bind-
ing and encompasses the whole human genome sequence.
The  in silico searching of the genome sequence provides
another way to identify target genes. An essential prerequisite
for the direct modulation of transcription by PPAR ligands is
the location of at least one activated PPAR protein close to the
transcription start site (TSS) of the respective primary PPAR
target gene. This is commonly achieved through the specific
binding of PPARs to a PPRE and DNA-looping towards the
TSS [10]. In detail, the DNA-binding domain of PPARs con-
tacts the major groove of a double-stranded hexameric DNA
sequence with the optimal AGGTCA core binding sequence.
PPARs bind to DNA as heterodimers with the NR retinoid X
receptor (RXR) [11]. PPREs are therefore formed by two hex-
americ core binding motifs in a direct repeat orientation with
an optimal spacing of one nucleotide (DR1), where PPAR
occupies the 5'-motif [12]. However, characterization of
PPREs from regulated gene promoters has resulted in a large
collection of PPREs that deviate significantly from this con-
sensus sequence. The ubiquity of such PPRE-like sequences
on a whole genome level is in contrast to the number of poten-
tial PPAR target genes in a physiological context (a few hun-
dred to a few thousand per tissue [13] and the number of
receptor molecules (a few thousand per cell). A recent effort
to better model the binding preferences of PPARs used posi-
tion weight matrices to describe all published PPREs [14].
However, such an approach has limited ability to predict
bona fide PPAR binding in vivo.
In addition to binding strength, a number of additional
parameters could influence the functionality of a PPRE. One
common trend in location of transcription factor binding sites
is a positional bias towards the TSS. This would be apparent
from the collection of identified PPREs, but is in contrast with
a multi-genome comparison of NR binding site distribution
[15]. Furthermore, a common approach for the detection of
functional binding sites is to rely on conservation. However,
maintenance of responsiveness may not require conservation
of exact binding site composition. In contrast, there is also
evidence to indicate that regulatory regions may evolve with
more flexible constraints. Such a stabilizing model of evolu-
tion was proposed based on conservation patterns in the Dro-
sophila eve gene enhancer, where patterns and locations of
binding sites were shown to be divergent, but maintain iden-
tical patterns of expression [16]. This turnover has been stud-
ied with computer simulations demonstrating that
appearance and fixation of novel binding sites occurs in short
evolutionary time frames [17].
In this study, we performed an experiment-based informatics
approach for the reliable identification of PPREs and PPAR
target genes. We chose to take an unbiased approach for the
characterization of PPRE binding variants, utilizing an exper-
imental binding strength dataset. As a first step, we per-
formed in silico screening and binding strength prediction of
PPREs in eight known PPAR target genes and found for each
four to nine PPREs within a 10 kB distance of their respective
TSSs. Seventeen of these (in total 23) genomic regions were
found to be functional in liver- and kidney-derived cells and
12 of them associated with PPARα and its partner proteins.
Three of these regions are located in the uncoupling protein 3
(UCP3) gene, for which so far no PPREs had been identified.
Next a collection of 38 validated PPAR target genes in human
was used for the detection of features of binding site compo-
sition in these genes. In conclusion, significant diversification
of binding site composition between species was often
observed. However, typically these genes contain strong or
multiple medium strength PPREs. Based on this insight, we
screened the whole of human chromosome 19 (containing
1,445 annotated genes) and the corresponding syntenic
regions in the mouse genome (956 known orthologs) and
found that our PPAR responsiveness criteria were passed by
116 genes in both species. Under more stringent criteria 8.7%
of human genes in the same chromosome would likely be
PPAR targets. All six genes, chosen to be representative from
this panel, were shown to be primary PPARα targets. For one
of these, the longevity-assurance homologue 1 (LASS1) gene,
we demonstrate that a genomic region containing two PPREs
is functional and recruits PPARα as well as its partner
proteins.
Results
A PPRE binding strength prediction scheme
Recently, we characterized the in vitro binding preferences of
the three PPAR subtypes on a panel of 39 systematic single
nucleotide variations of the consensus DR1-type PPRE
(AGGTCAAAGGTCA) [18]. Based on this analysis we subdi-
vided the single nucleotide variants into three classes (Table
1). Sequences in class I are bound by the PPAR subtypes with
a  s t r e n g t h  o f  7 5  ±  1 5 %  o f  t h a t  o f  t h e  c o n s e n s u s  P P R E ;
sequences in class II are bound with a strength of 45 ± 15% of
that of the consensus PPRE; and sequences in class III are
bound with a strength of 15 ± 15% of that of the consensus
PPRE. Although the overall binding pattern of the three PPAR
subtypes showed no major differences, some variations gave
rise to a PPAR subtype-specific classification. We observed
that the number and class of variations seem to correlate with
experimental binding. Therefore, we decided to take the con-
cept further to create a classifier for PPREs based on binding
data. We sorted a total of 136 DR1-type response elements
(REs; including combinations of multiple variations)http://genomebiology.com/2007/8/7/R147 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. R147.3
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Genome Biology 2007, 8:R147
according to the number and class of variations (Figure 1).
The in vitro binding strength to these REs in relation to the
consensus DR1-type PPRE was determined by gelshift assays
for the RXR heterodimers of all three PPAR subtypes. For
each category in Figure 1 the average of the relative binding
strength was determined (based on 6 to 47 RE/PPAR subtype
combinations). REs with 1/0/0, 2/0/0 and 0/1/0 variations
(where the numbers indicate the number of variations for the
classes I, II and III, respectively) bound the receptor strongly
(67%, 43% and 39% relative binding, respectively), REs with
3/0/0, 1/1/0 and 0/0/1 variations were medium PPREs
(29%, 22% and 20%, respectively) and REs with 0/2/0, 2/1/
0, 1/0/1, 3/1/0 and 4/0/0 variations were considered to be
weak PPREs (8%, 4%, 3%, 1% and 1%, respectively). We set
1% as a cut-off limit. Representative DR1-type REs with
increasing numbers of more drastic variations were examined
as well (Additional data file 1), but these elements were not
considered as functional PPREs. Please note that the pub-
lished PPRE of the acyl-CoA oxidase 1 (ACOX1) gene [19]
belongs to the latter list.
The performance of the classifier in predicting novel binding
sites was simulated by random sampling of the experimental
data in Figure 1 and Additional data file 1 into a training set
that was used to re-calculate the category averages at each ini-
tialization (approximately 10% of data was used in training)
and a validation set that can be used in testing (rest of the
data). Representative data from 10 rounds of simulation are
shown in Additional data file 2. Interestingly, the category
averages were relatively robust to changes in the set of
sequences used to calculate the average. This suggests that
the introduction of further sequences that belong to the same
category will not drastically affect the classifier performance.
Comparison of PPRE classifier to matrix methods
In order to compare the classifier to the traditional matrix
methods, we created a position-specific weight matrix
(PSWM) and a position-specific affinity matrix (PSAM) using
the PPARγ data from Figure 1 and Additional data file 1. For
the PSWM we took all medium and strong PPREs with multi-
ple variations from Figure 1, calculated base pair frequencies
and converted these to matrix values by logarithmic transfor-
mation, where an equal background frequency was assumed
and a pseudocount of 0.01 was included for non-observed
base-pairs (bp). We chose not to include the systematic single
nucleotide variation screen data, since this would have biased
the matrix strongly towards the consensus PPRE. In total, 20
sequences were used to construct the matrix, which is in the
order of known binding sites typically used as a basis of such
matrices in databases, such as JASPAR or TRANSFAC. The
PSAM was chosen to represent a matrix method utilizing the
single nucleotide screening data, in order to see if these data
are sufficient to capture the binding preferences of multiple
variation data.
Table 1
Systematic variation from consensus DR1-type PPRE
Percent binding strength PPRE position
1 2 3 4 5 6 7 8 9 10 11 12 13
PPARα
Consensus (90-100) A/G G G T A/C A A A G G T C A
Class I (60-90) T C G T G T C/G A/G G
Class II (30-60) C T A/T A/C/G T T C/G C A/C/T T C/T
Class III (0-30) A/C C/G T A/C A
PPARγ
Consensus (90-100) A/G G G T C/G A A A G G T C A
Class I (60-90) C/G A/T T G T C/G A/G/T G
Class II (30-60) C/T A/T T A C C A/C/T C/T
Class III (0-30) C A/C C/G/T G T A/C A
PPARβ/δ
Consensus (90-100) A/G G G T C A A A G G T C A
Class I (60-90) C/G G/T T G T G/T
Class II (30-60) C A/T T A A A/T C/G A G/C/T
Class III (0-30) T C A/C C/G/T C/G C/T C A/C A
The binding strengths of in vitro translated PPAR-RXR heterodimers to 39 systematic variations of the DR1-type consensus PPRE 
AGGTCAAAGGTCA were determined by gelshift assays in reference to this consensus PPRE. Based on their average binding strength, all variations 
are sorted into three classes.R147.4 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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Figure 1 (see legend on next page)
PPAR Relative PPAR Relative PPAR / Relative Mean SD Conclusion
E R   g n o r t s 9 0 , 0 7 6 , 0 g n i d n i b g n i d n i b g n i d n i b 0 / 0 / 1   y r o g e t a C
T GGTCAAAGGTCA 0 , 7 9 AGGC CAAAGGTCA 0 , 6 9 AGGC CAAAGGTCA 0 , 6 2
AGC TCAAAGGTCA 0 , 8 3 AGGG CAAAGGTCA 0 , 6 9 AGGG CAAAGGTCA 0 , 6 4
AGGTG AAAGGTCA 0 , 7 5 AGGTA AAAGGTCA 0 , 6 9 AGGTG AAAGGTCA 0 , 7 2
AGGTCAT A G G T C A 0,72 A G G T T AAAGGTCA 0 , 8 0 AGGTT AAAGGTCA 0 , 6 4
AGGTCAAG GGTCA 0 , 5 5 AGGTCAT A G G T C A 0,76 A G G T C A T A G G T C A 0,57
AGGTCAAAGT TCA 0 , 6 0 AGGTCAAG GGTCA 0 , 7 5 AGGTCAAG GGTCA 0 , 6 0
AGGTCAAAGGTA A 0 , 5 9 AGGTCAAAGT TCA 0 , 8 1 AGGTCAAAGT TCA 0 , 5 6
AGGTCAAAGGTG A 0 , 6 2 AGGTCAAAGGC C A 0,61 A G G T C A A A G G T T A0 , 6 2
AGGTCAAAGGTCG 0,60 A G G T C A A A G G G C A 0,63 A G G T C A A A G G T G A0 , 5 8
AGGTCAAAG G C CA 0 , 5 6 AGGTCAAAGGTA A0 , 6 6
AGGTCAAAGGG C A 0,61 AGGTCAAAGGTG A0 , 6 6
AGGTCAAAGGTT A0 , 5 8
AGGTCAAAGGTCG 0,89
0,43 0,09 Strong RE
C GGTCAAAGGTCA 0 , 3 1 C GGTCAAAGGTCA 0 , 5 4 C GGTCAAAGGTCA 0 , 5 4
A T GTCAAAGGTCA 0 , 4 5 T GGTCAAAGGTCA 0 , 3 4 AA GTCAAAGGTCA 0 , 4 0
AGT T C A A A G G T C A 0,37 A A GTCAAAGGTCA 0 , 5 1 AT GTCAAAGGTCA 0 , 5 0
AGA T C A A A G G T C A 0,40 A T GTCAAAGGTCA 0 , 5 3 AGT TCAAAGGTCA 0 , 2 8
AGGC CAAAGGTCA 0 , 2 6 AGT TCAAAGGTCA 0 , 4 3 AGGA CAAAGGTCA 0 , 4 2
AGGG AAAAGGTCA 0 , 4 0 AGGA CAAAGGTCA 0 , 4 9 AGGTA AAAGGTCA 0 , 5 4
AGGG CAAAGGTCA 0 , 2 7 AGGTCAC A G G T C A 0,40 A G G T C A A A A G T C A 0,33
AGGA CAAAGGTCA 0 , 5 7 AGGTCAAC GGTCA 0 , 4 7 AGGTCAAAT G T C A 0,27
AGGTT AAAGGTCA 0 , 3 7 AGGTCAAAC G T C A 0,47 A G G T C A A A G G C C A 0,33
AGGTCT AAGGTCA 0 , 4 8 AGGTCAAAT G T C A 0,62 A G G T C A A A G G T A A0 , 3 7
AGGTCAC A G G T C A 0,42 A G G T C A A A A G T C A 0,59 A G G T C A A A G G T C C 0,49
AGGTCAG AGGTCA 0 , 4 5 AGGTCAAAGGTCC 0,58 A G G T C A A A G G T C T 0,43
AGGTCAAC GGTCA 0 , 3 7 AGGTCAAAGGTCT 0,56 A G G T C A A A G G T C G 0,53
AGGTCAAAA G T C A 0,49 T GGTCAAAGGTCA 0 , 2 8
AGGTCAAAC G T C A 0,39 A G G T C A A A G G G C A 0,38
AGGTCAAAT G T C A 0,39
AGGTCAAAGGTT A0 , 4 3
AGGTCAAAGGTCC 0,51
AGGTCAAAGGTCT 0,49
Category 2/0/0 0,39 0,15 Strong RE
AGGGAAAAGGTCA 0 , 5 0 AGGCTAAAGGTCA 0 , 2 5
AGGCTAAAGGTCA 0 , 5 4 GGGG CAAAGT TCA 0 , 2 1
GGGG CAAAGT TCA 0 , 4 6
AGGG GAAAGGTCG 0,27
GGGTT AAAGGG C A 0,60
GGGTGAAAGGTGG 0,26
Category 3/0/0 0,29 0,16 Medium RE
AGGTCAAG G T TCG 0,24 A G G GAA T A G G T C A 0,35 A G G T T AAAGT T G A0 , 2 5
AGGG CAAAGGCGA0 , 6 0
AGGG GAAAGGGAA0 , 0 9
AGGG CAAAGTCC A 0,18
AGGTT AAAGT T G A0 , 1 5
AGGTCAAG G T TCG 0,31
GGGTGAAAGT T TG 0,43
Category 1/1/0 0,21 0,10 Medium RE
T GGG CAAAGGTCA 0 , 3 4 T GGG CAAAGGTCA 0 , 4 6 T GGG CAAAGGTCA 0 , 2 2
AGGG AAT A G G T C A 0,25 A A GTCAAAGT T C A 0,23 A A GTCAT A G G T C A 0,16
GGGG CAAAGT T C A 0,28 A G G A CAAAGGC C A 0,13 A A GTCAAAGT TCA 0 , 2 2
AGGTCAAG GGTT A 0,12 A G G A GAAAGT T C A 0,26 A G G GAAAAGGTCA 0 , 2 3
AGGA CAAAGGC C A 0,10 A G G T C A C AGGTT A0 , 1 2 A G G T G AAAGGTA A0 , 1 6
GGGTT AAAGGG C A 0,32 G G G T G A A A T GTT A 0 , 1 0 AGGGCAAAGGTCG 0 , 1 5
Category 0/0/1 0,20 0,10 Medium RE
A A GTCAAAGGTCA 0 , 1 3 AC GTCAAAGGTCA 0 , 1 7 AC GTCAAAGGTCA 0 , 1 3
A C GTCAAAGGTCA 0 , 0 5 AGA TCAAAGGTCA 0 , 2 4 AGA TCAAAGGTCA 0 , 2 3
AGGTCC AAGGTCA 0 , 3 2 AGC TCAAAGGTCA 0 , 3 0 AGC TCAAAGGTCA 0 , 1 8
AGGTCG AAGGTCA 0 , 2 5 AGGTCC AAGGTCA 0 , 1 5 AGGTCC AAGGTCA 0 , 0 9
AGGTCAAT GGTCA 0 , 0 3 AGGTCG AAGGTCA 0 , 0 5 AGGTCG AAGGTCA 0 , 0 5
AGGTCAAAGA TCA 0 , 3 0 AGGTCT AAGGTCA 0 , 2 9 AGGTCT AAGGTCA 0 , 1 9
AGGTCAAAGC TCA 0 , 2 9 AGGTCAG A G G T C A 0,24 A G G T C A A C GGTCA 0 , 1 5
AGGTCAAAGGA C A 0,24 A G G T C A A T GGTCA 0 , 3 3 AGGTCAAT GGTCA 0 , 0 8
AGGTCAAAGA TCA 0 , 4 6 AGGTCAAAC G T C A 0,18
AGGTCAAAGC TCA 0 , 3 4 AGGTCAAAGA TCA 0 , 2 1
AGGTCAAAGGA C A 0,33 A G G T C A A A G C TCA 0 , 1 1
AGGTCAAAGGA C A 0,15
AGGTCAC A G G T C A 0,26
AGGTCAG A G G T C A 0,26
Category 0/2/0 0,08 0,07 Weak RE
AGT TAAAAGGTT A 0,00 G G G GAAAAGGTCC 0,13 A G G A CAAAGGC C A 0,00
AGGC CAG A G G T C A 0,06
GGGG AAAAGGTCC 0,09
AGGTCT AAGGTT A0 , 1 8
Category 2/1/0 0,04 0,05 Weak RE
GGGG CAAG GGTG A0 , 0 2
AGGGGAAG GGTCA 0 , 0 9 T GGTT AAAGGTT A0 , 1 0 T GGTT AAAGGTT A0 , 0 1
AGC T G AAAGGTA A0 , 0 0 T GGTGAAAGT T A A0 , 0 0 A G T T A AAAGGTT A0 , 0 0
AGGAGAAAGT TCA 0 , 2 0 T GGTCAAAGT TCG 0,09 A G G AGAAAGT TCA 0 , 1 0
AGGGGAAAGGTA A0 , 1 2 T GGTGAAAGGTGG 0,01 A G G GAA T A G G T C A 0,06
GGGTG A G AGGTG A 0,07 G A GTCAAAGT T G A0 , 0 1 A G G GGAAAGGTCG 0,12
AGGTT AAAGT T G A 0,10 G T GTA AAAGGTCG 0,03 A G G G CAAG GGTCT 0,00
AGGTCAC AGGTT A 0,08 A G C TGAAAGT T A A 0,00 A G G G CAAAGTCC A 0,06
T GGC CAAAGGG C A 0,05 G G TCCAAAGGG C A 0,02 G G G C CAAG GGTCC 0,00
AGGG CAAAGTCC A 0,13 A G T T A AAAGGTT A0 , 0 0 G G G T G AAAT GTT A0 , 0 0
AGGTG AAAGGG C C 0,11 A G T TCAAAGT T T A0 , 0 2 G G G T G AAAGGTGG 0,03
AGGAAAAAGGC C A 0,00 A G G T C A A G G T TCG 0,08
GGGA GAAAGGGAA0 , 0 0
GGGA CAAAGGTTG 0,09
GGGC CAAG GGTCC 0,03
AGGG CAAG GGTCT 0,00
AGGTA AAATTTCA 0 , 0 0
GGGTGAAAGGGAC 0,01
GGGTCAAC GGGTA0 , 0 0
GGGTGAAAT GTGC 0,00
Category 1/0/1 0,03 0,03 Weak RE
G C GTCAAG G G T C A 0,01 G C G C CAAAGGTCA 0 , 0 8 GC G C CAAAGGTCA 0 , 0 1
GGGTCAAG G A T C A 0,02 G C GTCAAG G G T C A 0,04 G C GTCAAG GGTCA 0 , 0 0
AGGTCAAAGA T G A 0,01 A G C TGAAAGGTA A0 , 0 0 A G G C CAG A G G T C A 0,04
GGGTCAAAGC T G A 0,00 A G G C CAG AGGTCA 0 , 1 1 AGGTA A G A G G T C A 0,02
AGGTA A G A G G T C A 0,10 G G G T C A A G G A TCA 0 , 0 0
AGGTGG AAGGTA A0 , 0 0 A G G T C A A A G A T G A0 , 0 0
GGGTGAG AGGTG A 0 , 0 3 GGGTCAAAGC T G A0 , 0 0
GGGTCAAG G A TCA 0 , 0 6
AGGTCAAAGA T G A0 , 0 2
GGGTCAAAGC T G A0 , 0 3
Category 4/0/0 0,011 0,02 Weak RE
T GGTG AAAGT T A A 0,00 A G G G CAAG GGTAG 0,02
AGC T G AAAGT T A A 0,00 G G G G CAAAGGGTG 0,04
GGGTA A T AGT G A A0 , 0 0 G G G T T AAAGGGGG 0,02
AGGTGAAAGTGTG 0,00
0,010 0,02             Weak RE
T GGAGA T A G G T C A 0,00 T GGTCAAG G TGC A 0,04 A G G GGA T AGGG C A 0,00
A TCT T AAG G G T C A 0,00 G G G CTAAAT GTG A0 , 0 0 A G G GGAAAGGGGA0 , 0 2
AGGG CAAG GGTAG 0,01 A G G C CAAG GGTTC 0,00 G G G T G A T AGGGTA0 , 0 0
AGGGGAAAGGGAA 0,05 A G G G GAAAGGCAC 0,00
GGGTG AAAGGGAC 0A G G T T A TGGGTG A0 , 0 0
AGGTCAAAGTCAC 0A G G T T AAGTGTG A0 , 0 0
AGGTGATGGGTGC 0,00
GGGTCAAGTG GTA0 , 0 4
AGGTCAAAGTCAC 0,01
Category 0/1/0
Category 3/1/0http://genomebiology.com/2007/8/7/R147 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. R147.5
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Genome Biology 2007, 8:R147
We compared the three methods first on the level of their abil-
ity to detect binding. True positive and false positive rates
(TPRs and FPRs, respectively) were calculated using different
cut-off values for each method and are represented in the
form of a receiver operating characteristic (ROC) curve (Fig-
ure 2a). The line of no discrimination is indicated as a diago-
nal line; perfect performance would give a TPR of 1 and FPR
of 0. For all methods an optimum performance was detected
with FPR from 20-30% and TPR varying from around 90%
for the PPRE classifier to 75% for the PSAM. For clarity, one
representative classifier curve out of ten calculated is shown.
Next we wanted to know whether the scores correlated with
experimental binding when comparing single and multiple
variation data. We examined this with correlation plots using
the PPARγ data as shown in Additional data file 3. In parallel,
we set a tolerance interval of 15% relative to the consensus
sequence for a match between predicted binding strength and
experimental binding (5%, if the predicted binding was less
than 15%) and calculated predictions by the different meth-
ods. The equations of the lines fitted to the single nucleotide
data (Additional data file 3) were used to correlate matrix
scores with binding strength. The ideal cut-off values based
on the ROC curves were used in the scoring and produced
respective data points in the ROC space (Figure 2b), this time
with TPR reflecting correct predictions (no underestimation,
if 1) and FPR reflecting overestimated values. Several data
points are given for the classifier, representing ten separate
Testing the RE classification scheme on natural DR1-type sequences Figure 1 (see previous page)
Testing the RE classification scheme on natural DR1-type sequences. The average binding strength of in vitro translated PPAR-RXR heterodimers to DR1-
type PPREs was determined by gelshift assays in reference to the consensus PPRE AGGTCAAAGGTCA, including all categories (that is, combinations of 
the classes I, II and III) that resulted in an average binding of at least 1%. Variations from the consensus PPRE are highlighted in green for PPARα, in dark 
blue for PPARγ and in light blue for PPARβ/δ. In total, the in vitro binding data of 136 different REs were used (the non-binding DR1-type REs are shown in 
Additional data file 1), with a minimum of six sequences for each category. SD, standard deviation.
ROC curves comparing in silico methods Figure 2
ROC curves comparing in silico methods. (a) A PSWM constructed from 20 medium and strong PPREs that contain multiple variations, and a PSAM 
constructed using the single nucleotide data and ten initializations of PPRE classifier created based on Table 1 and random sampling of Figure 1 and 
Additional data file 1 were compared for their ability to detect binding. True positive rates (TPRs) and false positive rates (FPRs) were calculated, with false 
positives given when no binding was detected despite prediction, and false negatives given when binding was detected but not predicted (correlation of 
matrix scores to predicted binding was done based on lines fitted to correlation plots shown in Additional data file 3). A line of no discrimination is a 
diagonal line and optimum performance approaches the value (0, 1). For clarity, only one representative instance of a PPRE classifier is shown in (a). (b) To 
assess how good the predicted experimental binding estimates were, the performance of the method used was tested with a 15% tolerance interval for a 
match to experimental binding (5% when prediction was 15% or less) using a single cut-off (the optimal cut-off was 3% for the classifier, 25% or a score of 
0.0000015 for PSAM, and 20% or a score of 4.7 for PSWM) and calculating again the FPR and TPR for each method. False positives in this case represented 
predictions that were too high and false negatives predictions that were too low.
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initializations with the sampling of training and validation
sets.
When comparing the performance of the PSWM between the
different datasets (Additional data file 3), a rather clear dis-
tinction between the scores of single nucleotide variations
(medium and strong PPREs) and the non-binding PPRE
classes was observed. The partition of single nucleotide data
into two groups of data points shows that the matrix handles
variations that were not included in the PPRE set by penaliz-
ing these with a constant negative score. Values above 6 still
separated quite well from the data points of the last panel.
However, the multiple variation data that include weak to
strong PPREs were not well resolved by the matrix. Instead a
large amount of weak binding sites received high matrix
scores, which seems to cause the high FPR rate.
Despite the fit to the single nucleotide data, the PSAM did not
offer a significant improvement to the prediction of multiple
variations and also had problems differentiating the non-
binding PPREs. This is evident by examining the data points
between matrix values 0.000001 and 0.000002. This inter-
val includes weak to strong PPREs with identical matrix
scores leading to an increased FPR rate. The classifier corre-
lation was weaker for single nucleotide data compared to the
PSAM, but the same variation was preserved for multiple var-
iation data. A clear separation between weak PPREs and
those of medium and strong strength was achieved. The
ability to use a PPRE prediction that also correlates with
binding strength is a clear advantage for the evaluation of
putative binding site content of target genes. Based on the dif-
ferent comparisons, we chose the PPRE classifier as most
suited for the follow-up analysis of PPAR target genes.
In silico analysis of known PPAR target genes
We tested the performance of our PPRE binding strength pre-
diction scheme on eight primary PPAR target genes. We
selected the well-known up-regulated human genes ACOX1
[19],  carnitine palmitoyl transferase (CPT)  1B  [20] and
PPARα [21] and the established down-regulated gene apoli-
poprotein  (APO)  C3  [22]. The genes angiopoietin-like 4
(ANGPLT4) [23], sulfotransferase (SULT) 2A1 [24] and Rev-
ErbAα (RVRα) [25] were chosen because their PPREs were at
unusual positions, such as in an intron or more than 5 kB
upstream of their TSS, or of unusual structure, such as a
direct repeat with two intervening nucleotides (DR2). Finally,
the gene UCP3 [26] was included, because despite being an
established PPAR target, no PPRE had yet been characterized
within its previously studied regulatory regions. Therefore,
the latter gene was a specific challenge to our PPRE predic-
tion approach. By real-time quantitative PCR we confirmed
the inducibility of all eight genes by PPAR ligands (Additional
data file 4) and demonstrated in parallel that our experimen-
tal systems, the human cell lines HEK293 (embryonal kidney)
and HepG2 (hepatocarcinoma), with the exception of the
APOC3 gene in HEK293 cells, are well suited for the investi-
gation of these genes.
For the eight PPAR target genes we performed an in silico
PPRE search, which spanned 10 kB upstream and down-
stream of the respective TSS (Figure 3). All PPRE categories
that included PPREs with 5% or more binding strength for
each subtype are shown. The categories resulting in 1-5% of
binding (1/0/1, 3/1/0 and 4/0/0) were indicated only when
the PPREs were conserved in the mouse genome. Based on
sequence alignments of the human and mouse genome, the
evolutionary conservation of all putative REs was evaluated
on the level of the RE itself and the level of its flanking
sequence (± 50 bp). As a result, we found 5 REs in each of the
genes  ACOX1,  CPT1B,  SULT2A1  and  ANGPTL4, 9 in the
APOC3 gene, 4 in the PPARα gene, 7 in the RVRα gene and 6
in the UCP3 gene, giving rise to a total of 46 REs in the 160 kB
genomic sequence examined. The distribution of the putative
REs, relative to the TSS, was roughly equal, since 21 and 25
were found in the upstream regions and downstream areas,
respectively. In a cross-species comparison (mouse to
human), 10 of the 46 REs were found to be evolutionarily con-
served and a further 6 REs were located in conserved regions.
Our  in silico screening found the published PPREs of the
genes ANGPTL4, APOC3 and CPT1B as evolutionarily con-
served REs and the published PPREs of the genes SULT2A1
and PPARα as non-conserved. As mentioned above, the pub-
lished RE of the ACOX1 gene did not pass our in silico screen-
ing parameters and we confirmed by gelshift assays that it
does not bind PPARs (Additional data file 1). This observation
concurs with a previous report [27]. However, in that study it
was claimed that the human ACOX1 gene may not be an active
PPAR target, whereas here we show that the gene is regulated
by PPARs and suggest five new binding sites, of which one is
located in an evolutionarily conserved area of intron 1.
In silico analysis of selected primary PPAR target genes Figure 3 (see following page)
In silico analysis of selected primary PPAR target genes. Overview of the genomic organization of eight human PPAR target genes; 10 kB upstream and 
downstream of the TSSs are shown (horizontal black line). Putative REs (red boxes, no conservation; orange boxes, within conserved area; yellow boxes, 
conserved) were identified using the classifier by in silico screening of the genomic sequences and are classified according to their degree of conservation 
compared to the orthologous mouse gene. Already published PPREs are indicated by an asterisk. For each predicted RE the calculated binding strengths of 
PPARα (green), PPARγ (dark blue) and PPARβ/δ (light blue) in reference to a consensus DR1-type PPRE are represented by column height. All putative 
PPRE sequences are available on request. For the UCP3 gene REs, the average in vitro DNA binding strength of PPAR-RXR heterodimers was also 
determined by gelshift experiments and is shown in the same color code scheme. Horizontal red bars indicate the genomic regions that were subcloned 
for reporter gene assays (Figure 4) and were analyzed by ChIP assays (Figure 5).http://genomebiology.com/2007/8/7/R147 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. R147.7
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Figure 3 (see legend on previous page)
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The in silico binding strength predictions were confirmed by
gelshift assays for the six REs of the UCP3  gene (novel
sequences that had not been used for average calculations in
Figure 1). Comparing the experimentally determined and the
calculated values, all predicted binding sites match the exper-
imentally determined binding strength with a deviation of
less than 15%.
Taken together, in silico screening predicts that, for each of
the eight tested PPAR target genes, there are four to nine
PPREs within 10 kB of their respective TSSs, of which at least
one is a strong PPRE. The example of the UCP3 gene demon-
strates the good correlation between in silico prediction of
PPREs and actual in vitro binding of PPAR-RXR
heterodimers.
Functionality of PPAR responsive genomic regions
We selected within the regulatory regions of the eight PPAR
target genes 10 proximal REs (within 1 kB of the TSS), 10 REs
further upstream and 10 REs further downstream (the ele-
ment of the APOA1 promoter element was counted as a prox-
imal RE because the gene is a known responding gene [28]).
These REs are contained within 23 genomic regions (each
approximately 300 bp in length; for locations see Figure 3
and Table 2), which we cloned by PCR and fused with the thy-
midine kinase promoter driving the luciferase reporter gene.
We included the ACOX1 published region, in which we do not
predict a PPRE, as a negative control. The activity of the con-
structs in the absence or presence of PPAR subtype expres-
sion vectors in response to PPAR subtype-specific ligands was
tested by reporter gene assays in HEK293 and HepG2 cells
(Figure 4). Nine of the genomic regions are located within 1
kB of their respective TSSs (Figure 4a,d). With the exception
of the RVRα gene TSS, which contains a reported DR2-type
PPRE, eight of these regions displayed, in at least one of the
two cell lines, significant inducibility by PPAR ligands. The
region of the human CPT1B gene was inducible by all three
PPAR subtype-specific ligands in both cell lines, whereas the
seven other regions show PPAR subtype- and cell type-spe-
cific profiles. An increase in the basal activity compared to
empty cloning vector and its subsequent loss due to PPAR
over-expression were observed with the proximal regions of
the genes APOC3 and UPC3 in both cell lines as well as in
HepG2 cells with the intron 1-containing region of the ACOX1
gene and the proximal region of the APOA1 gene. This effect
may reflect the attraction of constitutively active transcrip-
tion factors, such as other nuclear receptors that recognize
DR1-type REs, for example, HNF4α, to the respective
genomic regions and their subsequent displacement [22].
The cellular context may permit stronger activation by the
displaced transcription factor, for example, due to higher
expression of favored coregulator interaction partners. This
switching of activating transcription factor to the binding site
could offer one explanation for the observed change in the
basal expression level.
Of the nine upstream regions, the region of the SULT2A1 gene
was shown to be the most active (Figure 4b,e). In both cell
lines over-expression of PPARs clearly increased this frag-
ment's basal activity as well as significant inducibility by all
three PPAR ligands. A similar observation was made in
HepG2 cells for the distal region of the UCP3 gene, an effect
that was far more modest in HEK293 cells. In contrast, nei-
ther the distal regions of the genes ACOX1 and RVRα nor the
region containing the published PPRE of the gene ACOX1 dis-
played any inducibility by PPAR ligands in either of the two
cells lines. Therefore, they can be considered as negative con-
trols. In addition, the distal regions of the genes ANGPTL4
and APOC3 were only inducible in HEK293 cells, whereas the
PPARα gene's putative PPRE-containing region responded
only in HepG2 cells to GW501516 treatment. Interestingly, in
HEK293 cells, the distal regions of the genes ANGPLT4,
APOC3 and PPARα showed the already described effects of
increased basal activity with endogenous activators and sub-
sequent suppression of the activity by PPAR subtype over-
expression.
Of the five downstream regions, the intron 2 region of the
ACOX1 gene and the cluster region of the ANGPTL4 gene
(containing four putative PPREs) displayed a clear response
to all three PPAR ligands in both cell lines. In contrast, the
inducibility of the intronic region of the APOC3 gene was far
more modest (Figure 4c,f). Individual mutagenesis of the
ANGPLT4 REs was carried out and this resulted in reduced
activity, thus demonstrating that the other REs, in addition to
the published PPRE, contribute to the responsiveness of this
region (data not shown). Finally, the cluster and intronic
region of the UCP3 gene responded only in HEK293 cells to
GW501516 treatment.
In summary, of the 23 investigated genomic regions contain-
ing putative PPREs, up to 17 display significant inducibility in
the presence of PPAR ligands (Table 3).
Association of PPARs and their partner proteins to 
PPRE-containing regions
The same 23 genomic regions of the eight PPAR target genes
w e r e  i n v e s t i g a t e d  b y  c h r o matin immuno-precipitation
(ChIP) assays with chromatin extracts from HEK293 cells (or
from HepG2 cells for regions from the APOC3 gene) that were
treated with solvent or for 120 minutes with the PPARα lig-
and GW7647 (Figure 5). We assessed these regions for the
binding of PPARα, its partner receptor RXRα and pPol II (the
latter as a sign for a direct connection between the RE-con-
taining region and the TSS). Chromatin templates were ana-
lyzed by quantitative real-time PCR and the specificity of the
antibodies for the three proteins was compared with the non-
specific background binding to IgG. Of the 23 tested regions,
the region of the CPT1B gene, the distal and published region
of the ACOX1 gene, the distal 1, distal 2 and intronic region of
the APOC3 gene and the cluster of the UCP3 gene did not
show specific binding of any of the three proteins. For the twohttp://genomebiology.com/2007/8/7/R147 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. R147.9
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Table 2
Genomic PCR primers
Gene (region) Location Primer sequences (5'-3')
ACOX1 (distal) -4919 to -4643 TGAGCTCTTGATCTCCTCCTCAGAGTCATAG
GAGTCTAGACTGGCAATCTTAGCAGAGTTC
ACOX1 (published) -1646 to -1374 TGAGCTCTTGAACTAGAAGGTCAGCTGTC
GGGTCTAGACTAGCCTGTCTGTAGTCTGTG
ACOX1 (intron 1) +599 to +716 TGAGCTCTTGTGATTCAGGGAGGGTGGAAC
GGGTCTAGACTGGCTGCGAGTGAGGAAG
ACOX1 (intron 2) +2822 to +3154 TGAGCTCTTGAGATAGAGTAACTCCTCCTAG
GAGTCTAGAGAAGTGTGTCAAAGGGTGTG
ANGPTL4 (distal) -6765 to -6535 TGAGCTCTTGAACTAGAAGGTCAGCTGTC
GAGTCTAGAATACACTCATGCAGGGTGAGG
ANGPTL4 (cluster) +2829 to +3610 TGAGCTCTTCTCCGTTCATCTCGAACCAC
GAGTCTAGACATCTCAGAGGCTCTGCCTG
APOC3 (distal 1) -6429 to -6143 TGAGCTCTTGCTCAGGCGATAGTTAGAAG
GAGTCTAGACTGGATGGTCCCACTCCAGTG
APOC3 (distal 2) -4249 to -3886 TGAGCTCTTGACTATGAGGTGACATCCAGG
GAGTCTAGAGGACACACAGGCAGTACGTG
APOC3 (proximal) -870 to -568 TGAGCTCTTGGCAGTGAGGGCTGCTCTTC
GGGTCTAGACATCTCTGGGTTTCAATCCAG
APOC3 (published) -262 to -3 ATTTCTAGACAGTCAGCTAGGAAGGAATGAG
GGGTCTAGACTAGGGATGAACTGAGCAGAC
APOC3 (intron) +2424 to +2722 TGAGCTCTTGATCACACAACTAATCAATCCTC
GAGTCTAGACTCAACTTCACTGGACGACAG
APOA1 (proximal) +7701 to +8022 (relative to APOC3 TSS) TGAGCTCTTCCTTCTCGCAGTCTCTAAGC
GAGTCTAGAGCCAACACAATGGACAATGG
CPTIB -306 to -64 ATTTCTAGACAGAGTCTCGTGAGGATGGTG
GGGTCTAGAGTTAGCGTTCATGCTGCCAG
PPARa (distal) -1376 to -1156 TGAGCTCTTCTGGCTAACATGTGCAAGAG
GGGTCTAGACACTGTGCTATTTGTGGCAG
PPARa(proximal) -938 to -634 TGAGCTCTTCTCCTTGCTCTGGCAGAGTC
GGGTCTAGACTCAGAAGTGCGTAGGGTG
RVRa(distal) -7279 to -7040 TGAGCTCTTGACCTTCCCAAGCCAAGAAC
GAGTCTAGACACTAACCTCACAGACCACTG
RVRa(proximal) -510 to -70 TGAGCTCTTCTGGAGGTGTTCTCCCTAAG
GTGTCTAGACTGCGCAACGACAAGACTG
RVRa(TSS) -510 to +119 (subcloned -266 to +119) TGAGCTCTTCTGGAGGTGTTCTCCCTAAG
GTGTCTAGATTTCACTCTGCCAATCTCAGC
SULT2A1 -6104 to -5797 ATTTCTAGACTTGAATGGAAATGCCTGCTC
GGGTCTAGAGACTGGGAAGTGGGAGGAGT
UCP3 (distal) -9680 to -9349 TGAGCTCTTCTCTAGTCTAAGTGCCTTGTC
GAGTCTAGAGTAACAGTGAGCCTCTGGTCTG
UCP3 (proximal) -396 to -89 TGAGCTCTTGTACCTATCTCATAGGATTGTG
GTGTCTAGAGTTGACAGCCTGATCACTTGAC
UCP3 (cluster) +2036 to +2303 TGAGCTCTTCAGGACTATGGTTGGACTGAAG
GGGTCTAGAGATGGGAGGAGGCAAGGAAG
UCP3 (intron) +5971 to +6236 TGAGCTCTTCTCGTGCTGAGCACTTTACAC
GAGTCTAGACACTTGTTGGGTCCATTCTAAC
LASS1 (region 1) -5297 to -4917 TGAGCTCTTCTGATGTGCAATCTCAGACAG
GAGTCTAGACTCAGTCTCCACCATGAAGG
LASS1 (region 2) -2819 to -2499 TGAGCTCTTCCTCCCAGATGTCACCATTG
GAGTCTAGACCTCTTTTGCCACTTCCCTC
LASS1 (region 3) -1389 to -978 TGAGCTCTTGTGGAACAGGAGCCATAGAG
GGGTCTAGACATCGAGGAAGACACTGGTC
Sequence and location of the primer pairs used for real-time PCR quantification of genomic regions containing putative REs within the nine PPAR 
target genes. The positions indicated are in relation to the respective annotated gene TSS. The same primers were used for subcloning; the gene-
specific sequences are indicated in bold.R147.10 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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regions of the ACOX1 gene this result confirmed their failure
in the previous functionality test (Figure 4). The 16 other
regions showed a significant association with PPARα in the
presence of ligand. When comparing the relative association
levels of PPARα under these conditions, we found that the
most prominent binding was to the region of the SULT2A1
gene, followed by the regions of the RVRα TSS and the prox-
imal region of the PPARα gene (Figure 5d). Interestingly, the
latter two regions as well as the proximal regions of the genes
APOA1 and UCP3, the distal region of the RVRα gene and the
distal and intronic region of the UCP3 gene even displayed
ligand-independent binding of PPARα. Similarly, a GW7647-
independent association of RXRα was found on the published
region of the APOC3 gene, on the proximal regions of the
genes APOA1, PPARα and UCP3 and on the distal regions of
the genes ANGPTL4 and UCP3. In contrast, no statistically
significant binding of pPol II, irrespective of the presence of
ligand, was found on the published region of the APOC3 gene
and in the distal regions of the genes ANGPTL4 and RVRα.
Taken together, PPARα and RXRα associate in living cells
with 16 of the 23 genomic regions. Thirteen of these regions
also associate with pPol II, twelve of which show functionality
in reporter gene assays (Figure 4, Table 3). With the exception
Extra-genomic functionality of the PPRE-containing promoter regions of PPAR target genes Figure 4
Extra-genomic functionality of the PPRE-containing promoter regions of PPAR target genes. Reporter gene assays were performed with extracts from (a-
c) HEK293 and (d-f) HepG2 cells that were transiently transfected with luciferase reporter constructs containing genomic regions of eight human PPAR 
target genes (please note that the APOC3 gene forms a cluster with the genes APOC1 and APOC4). These were co-transfected with empty expression 
vector (endogenous PPAR) or the indicated expression vectors for PPARα, PPARγ and PPARβ/δ. Cells were then treated for 16 h with solvent or PPAR 
subtype-specific ligands. Relative luciferase activity was determined and normalized to the activity of empty cloning vector control co-transfected with 
empty expression vector (dashed horizontal red line). The genomic regions were subdivided according to their location into close to TSS (a, d), upstream 
of TSS (b, e) and downstream of TSS (c, f); for further details see Figure 3 and Table 2. Columns represent the means of at least three experiments and 
bars indicate standard deviations. Two-tailed Student's t-tests were performed to determine the significance of the ligand induction in reference to solvent 
controls (*p < 0.05, **p < 0.01, ***p < 0.001).
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of the CPT1B gene, the tested PPAR target genes possess one
to three of these tested regions. The regions show neither
positional bias nor do they preferentially contain evolutionar-
ily conserved PPREs. However, each of them contains at least
one predicted medium or strong PPRE. Three of the twelve
fully functional regions, the ANGPTL4  cluster region, the
proximal region of the PPARα gene and the distal region of
the SULT2A1 gene, were already known, but we identified two
alternative regulatory regions for each of the genes ACOX1
and APOC3, and one for the RVRα gene. We also found one
additional regulatory region for the PPARα gene. Finally, for
the UCP3 gene, for which no regulatory regions had so far
been described to account for the effect of PPAR ligands on its
mRNA transcription, we identified three functional areas.
Clustering of PPAR target genes by self-organizing 
maps
The common feature of the eight investigated PPAR target
genes appears to be a prevalence for strong PPREs at a dis-
tance of up to 10 kB from the TSS. With the aim of extending
this conclusion, we next compared all human genes that are
known as primary PPAR targets. The genes were selected
according to the following criteria: mRNA or protein level
changes were reported for human cells or tissues; a PPRE was
described for the human gene and it was experimentally con-
firmed by either gelshift, reporter gene or ChIP assay. This
resulted in 30 additional genes, for which we performed in sil-
ico analysis for putative REs up to a distance of 10 kB from
their respective TSSs (as done for the first eight genes; see
Figure 3). In addition, for all of the 38 genes, the orthologous
mouse gene was investigated in the same way (Figures 6 and
7). From these data, overview figures for each gene were con-
structed that show the location of the PPREs (x-axis) and
their respective predicted binding strength (y-axis). In order
to reveal further characteristics of the genes and their PPREs,
such as overall similarity of their patterns and evolutionary
conservation, they were clustered using a self-organizing map
(SOM) algorithm followed by Sammon's mapping to illustrate
the clusters. The input dataset of the SOM consisted of six
variables, which are the sum of the predicted binding strength
(BS), the number of conserved strong and medium binding
sites (CS) and the number of weak binding sites (CW) both for
the human and the mouse gene (Additional data file 5). An
initial map resulted in four clusters, which were then each
Table 3
Functionality of genomic regions
Genomic region Predicted binding Response in RGA Association of 
PPARα
Association of 
RXRα
Association of 
pPol II
PPRE status
ACOX1 i n t r o n  1 S t r o n g +++++
APOC3 p r o x i m a l W e a k D o w n ++++
APOC3 published Medium Down + + - +
APOA1 p r o x i m a l W e a k + / d o w n ++++
CPT1B S t r o n g +---±
PPARα p r o x i m a l M e d i u m +++++
RVRα p r o x i m a l M e d i u m +++++
RVRα TSS No DR1 - +* +* +* -
UCP3 proximal Medium Down + + +
ACOX1 d i s t a l M e d i u m -----
ACOX1 p u b l i s h e d N o t  b i n d i n g -----
ANGPLT4 distal Weak +/down + + - +
APOC3 d i s t a l  1 M e d i u m ±----
APOC3 d i s t a l  2 M e d i u m ±----
PPARα d i s t a l S t r o n g+ / d o w n ++++
RVRα distal Weak - + + - ±
SULT2A1 S t r o n g +++++
UCP3 d i s t a l S t r o n g +++++
ACOX1 i n t r o n  2 M e d i u m +++++
ANGPTL4 cluster Strong + - + + +
APOC3 i n t r o n S t r o n g +---±
UCP3 c l u s t e r W e a k -----
UCP3 i n t r o n M e d i u mD o w n ++++
The data from reporter gene assay (RGA) and ChIP assays are summarized for each genomic region tested. The PPRE status indicates the conclusion 
drawn from the assays concerning the functionality of each region, with '+' assigned to functional regions, '-' to non-functional regions and '±' where 
the two assays were not in agreement. *Impossible to assess independent of adjacent region.R147.12 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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Figure 5 (see legend on next page)
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separated in the final map in up to five subclusters (Figures 6
and 7).
While the evolution of protein-coding sequences within
genomes is well understood, the same cannot be said of the
regions regulating transcription. The conservative model,
often utilized as a limit for in silico binding site predictions,
requires the strict preservation of binding site sequence and
location. However, recent research on enhancer evolution has
challenged this view. From these data, it appears possible to
maintain overall functional conservation of regulatory ele-
ments over long evolutionary times, despite having high
structural architecture turnover rates [16]. This feature has
not been widely explored with human target genes, but is
important to consider for target gene prediction. We
therefore sought to identify traces of binding site evolutionary
patterns in the clusters of this dataset. In general, clusters I
and II contain genes that are well conserved between human
and mouse, while the genes in cluster III are more divergent
and those in cluster IV show no evolutionary conservation of
PPREs.
Cluster I contains genes that carry multiple conserved PPREs
(Figure 6a). Cluster IA contains the genes ANGLPTL4, CPT1A
[29], lipoprotein lipase (LPL) [30] and phosphoenolpyruvate
carboxykinase (PEPCK) 1 [31], which have, in both human
and mouse, multiple conserved regions with strong REs.
While each gene contains a conserved medium/strong ele-
ment, a subset of genes expanded this set: human CPT1A and
mouse LPL show significant enrichment of de novo binding
sites compared to their orthologs. Cluster IB contains the
genes glycerol kinase (GK) [32] and UCP3, which have mul-
tiple conserved RE regions. The distal UCP3 PPRE is con-
served as a strong PPRE but is outside the 10 kB window in
mouse. The cluster of PPREs in the human GK  promoter
seems to have lost significance in the mouse. The lipoprotein
receptor-related protein 1 (LRP1) [33] gene represents clus-
ter IC, in which multiple conserved REs are strong in mouse
but weaker in human. Together with the genes GK and LRP1,
the genes found in cluster ID, caveolin 1 [34] and insulin-like
growth factor binding protein 1 (IGFBP1) [18], exhibit a
retain-loss pattern concerning conserved PPREs, where only
one species retained a cluster of strong PPREs. In the case of
the LRP1 gene, this appears to have arisen in the context of
several compensating de novo binding sites.
Cluster II differs from cluster I by having one or two strong or
medium conserved REs in human, which are found in a com-
parable strength and location in mouse (Figure 6b). This clus-
ter is subdivided into two clusters. Cluster IIA contains the
genes APOC3, CPT1B, CPT2 [35], cytochrome P450 (CYP)
1A1  [36],  3-hydroxy-3-methylglutaryl-CoA synthase 2
(HMGCS2) [37] and scavenger receptor B1 (SRB1) [38],
which have relatively comparable PPRE content. In contrast,
cluster IIB contains the genes adipose differentiation-related
protein (ADRP) [39], APOA1, G0/G1 switch gene 2 (G0S2)
[40], liver X receptor (LXR)α [41] and spermidine/spermine
N1-acetyltransferase (SSAT) [42], which exhibit an increase
in PPRE content in the mouse gene.
Cluster IIIA, which contains the genes cyclooxygenase 2
(COX2) [43] and semaphorin (SEMA) 6B [44], extends the
pattern observed above with an opposite trend; the human
ortholog contains one or two medium/strong REs, which are
conserved but only weak in the mouse (Figure 7a). Possible
compensating elements appeared in the mouse SEMA6B
gene, while this is not the case for the mouse COX2 gene. Also,
cluster IIIB contains one or two conserved REs, but they are
weak in both human and mouse. This cluster comprises the
genes  APOA2  [45],  APOA5  [46],  fatty acid desaturase 1
(FADS2) [47], pregnane X receptor (PXR) [48], RVRα and
solute carrier (SLC)  10A2  [49]. Interestingly, these genes
each have novel binding sites at nearly similar locations.
Cluster IV contains genes that carry one or more REs, but
none of them is conserved (Figure 7b). The ACOX1 gene rep-
resents cluster IVA, in which multiple strong, but non-con-
served, REs are found in both species. The genes resistin [50]
and SULT2A1 form cluster IVB; they have one or two strong
non-conserved REs in human and multiple REs in mouse.
The genes APOE [51] and PPARα are in cluster IVC, which is
characterized by one strong RE in the mouse ortholog and
one or more non-conserved REs in the human gene. In cluster
IVD are the genes CYP27A1 [52], glutathione S-transferase
(GST)  A2  [53],  transferrin  [54] and UDP-glycosyltrans-
ferase (UGT) 1A9 [55], which carry one or two medium, non-
conserved REs in both species. Finally, the cyclin-dependent
kinase inhibitor 2A (CDKN2A) [56] gene represents cluster
IVE, in which strong or medium non-conserved REs are
found in mouse and but only weak REs are found in human.
Association of genomic regions of PPAR target genes with PPARs and their partner proteins Figure 5 (see previous page)
Association of genomic regions of PPAR target genes with PPARs and their partner proteins. Chromatin was extracted from HEK293 cells that had been 
treated with solvent (DMSO) or for 120 minutes with 100 nM GW7647. The association of PPARα, RXRα and pPol II was monitored by ChIP assays with 
respective antibodies on genomic regions of the eight PPAR target genes that are (a) close to the TSS, (b) upstream of the TSS and (c) downstream of the 
TSS; for location see Figure 3 and Table 2. Since the APOC3 gene is not expressed in HEK293 cells, the data for its four genomic regions were obtained 
using chromatin derived from HepG2 cells. Real-time quantitative PCR was performed on chromatin templates and the fold change of the antibody-
precipitated template in relation to an IgG-precipitated specificity control template was calculated. (d) PPARα shows specific association with 15 of the 23 
tested regions and the relative association with these regions is shown. Columns represent means of at least three experiments and bars indicate standard 
deviations. Two-tailed Student's t-tests were performed to determine the significance of association in reference to IgG controls (*p < 0.05, **p < 0.01, 
***p < 0.001).R147.14 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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Figure 6 (see legend on next page)
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In summary, SOM clustering of the 38 presently known
human PPAR target genes sorts them into four clusters, of
which the first three contain different numbers of evolution-
arily conserved REs, while the 10 genes of cluster IV are char-
acterized by having non-conserved REs. Interestingly,
although for some genes a conservation of the PPRE pattern
is evident, significant diversity in the composition of PPREs is
visible as well.
Evolutionary preservation patterns of PPREs in the 
genes ACOX1 and ANGPLT4
In order to explore the evolutionary preservation patterns of
PPREs further, the genes ACOX1  and  ANGPLT4 from the
genomes of chicken, chimpanzee, dog, rat and zebrafish were
also analyzed (Figure 8). In the genome of the chimpanzee
(Pan troglodytes), the closest relative to human, four con-
served PPREs were located in the ACOX1 gene, but the intron
2 region is missing. The respective human PPRE is not con-
served in any of the species analyzed, suggesting that it is
human-specific. Mouse and rat (Rattus norvegicus) share
two PPREs, although both also contain a unique set of further
REs. The analysis of the ACOX1 gene in chicken (Gallus gal-
lus), dog (Canis familiaris) and zebrafish (Danio rerio) is in
accordance with the overall pattern of relatively species-spe-
cific composition of PPREs. Within mammals, the cluster of
intronic REs of the ANGPLT4 gene is rather well conserved.
The closest PPRE pattern in comparison to the human gene is
observed in the dog. Two intronic PPREs are also present in
rat, but a significant expansion in PPREs seems to have
occurred in this species, including a distal consensus RE. The
zebrafish ANGPLT4 gene is also profoundly enriched with
strong PPREs, whereas the chicken gene has a quite poor
PPRE content. Moreover, the loss of the published PPRE is
observed in the chimpanzee gene. Therefore, while this gene
is an example of a much more preserved PPRE pattern, signif-
icant diversification is evident amongst the genomes analyzed
and not all functional PPREs are conserved.
In conclusion, the SOM analysis and further genome compar-
isons together suggest that functional RE choice is evolution-
arily flexible with respect to first gaining and then
maintaining responsiveness to PPARs. In effect, integration
of the stabilizing selection model into target gene
identification and characterization may more faithfully iden-
tify PPAR targets.
Identifying PPAR target genes in human chromosome 
19
For the purpose of target gene identification, the SOM analy-
sis (Figures 6 and 7) indicated that either the presence of at
l e a s t  o n e  s t r o n g  P P R E  o r  m o re than two medium PPREs
within the 20 kB surrounding the annotated TSS of a gene is
a strong indication for a PPAR target gene. In this way, 28 out
of the 38 human genes (74%) would have been identified as
PPAR targets. Similarly, for 29 of these 38 genes (76%) the
analysis of their murine ortholog would have come to the
same conclusion. A combination of these two criteria (passing
the threshold in either the human or mouse ortholog) would
have identified 37 of the 38 genes (97%) as PPAR targets.
UGT1A9 could be detected from the list of genes having two
medium REs. While location clearly is not a major determi-
nant of PPRE functionality, the screening of these regions in
500 bp windows indicates modest enrichment in the proxi-
mal promoter (24% of genes have a medium/strong PPRE
close to the TSS; data not shown).
To explore this concept further, we selected the gene-dense
human chromosome 19 (63.8 MB, 1,445 known genes in
Ensembl, release 41) and its syntenic mouse regions (956
genes have known orthologs) and screened both species for
medium and strong PPREs (based on a PPARγ prediction).
We extracted from four human microarray datasets [8,57-59]
those genes located on chromosome 19 that were shown to be
regulated and determined whether these passed the criteria
derived from the 38 target genes (that is, having a strong
PPRE, a proximal medium PPRE or more than two medium
PPREs). Typically, each dataset contained 6 to 8 genes from
chromosome 19, out of which at least 5 (71-100%) passed the
criteria in either or both species, and typically 1 or 2 genes had
2 medium PPREs only. This implies that the sensitivity of
detecting targets based on our screen for medium and strong
PPREs is high.
The background frequency of strong PPREs calculated by the
total number of predicted strong PPREs divided by the length
of chromosome 19 was found to be 0.66 for the 20 kB region
considered for each gene, whereas that of medium or strong
PPREs is 1.3. Twenty percent of genes of chromosome 19 con-
tain a co-localizing strong PPRE and an additional four per-
c e n t  h a v e  m o r e  t h a n  t w o  medium PPREs or a proximal
medium PPRE. These numbers suggest a total of 4,000 to
5,000 targets for PPARs in the human genome, if no false
positives are assumed. A complete evaluation of the selectiv-
SOM analysis of established primary PPAR target genes, clusters I and II Figure 6 (see previous page)
SOM analysis of established primary PPAR target genes, clusters I and II. Overview of the genomic organization of 38 known human PPAR target genes 
(left) and their mouse orthologs (right); 10 kB upstream and downstream of the TSS are shown in this and Figure 7. Please note that for the mouse CYP1A1 
gene and the human FADS2 gene, there are discrepancies between the Ensembl (E) and NCBI (N) databases; therefore, both versions are shown. Putative 
PPREs (red boxes, no conservation; orange boxes, within conserved area; yellow boxes, conserved) were identified by in silico screening of the genomic 
sequences and are classified according to their degree of conservation between mouse and human. Already published PPREs are indicated by an asterisk. 
For each of the predicted PPREs, the calculated binding strengths of PPARα (green), PPARγ (dark blue) and PPARβ/δ (light blue) in reference to a 
consensus DR1-type PPRE are represented by column height. All putative PPRE sequences are available on request. The genes were sorted by SOM 
analysis with respect to overall PPRE pattern similarity and their evolutionary conservation into (a) cluster I and (b) cluster II.R147.16 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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Figure 7 (see legend on next page)
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ity is complicated by the restricted expression profiles of the
predicted genes, which prevents simple read-outs from
individual target tissues (regulation of only two genes from
chromosome 19 was detected on more than two microarrays
used earlier). We chose a focused list for further inspection,
by requiring detection in human and mouse. In total, 116
genes (12.1%) from chromosome 19 pass the filter (Table 4).
Furthermore, all 1,445 human genes were screened for high
enrichment of PPREs, that is, for assemblies of at least three
medium or strong PPREs (of which at least one was strong).
These even more stringent criteria were fulfilled by 50 genes
of both species (bold entries in Table 4) and an additional 75
human genes (Additional data file 6), a sample that repre-
sented 8.7% of all genes from human chromosome 19.
Comparing these lists with published microarray-derived
lists of target genes suggests interesting candidates in differ-
ent physiological contexts of PPARs, where genes showing
evidence of regulation have already been detected. PPARs
play a prominent role in lipid metabolism and homeostasis.
Genes detected from chromosome 19 represent diverse func-
tions, such as liberation and transport of lipids (hormone sen-
sitive lipase [58] and the fatty acid transporter genes
SLC27A5 and low density lipoprotein related receptor 3),
signaling molecules affecting lipid homeostasis (resistin and
the transcription factor gene CCAAT/enhancer binding pro-
tein [58], which is known to regulate leptin expression [60])
and the generation of modified lipids that may have signaling
roles (CYP4F8 functioning in ω-oxidation and LASS1 func-
tioning in ceramide synthesis). Genes with a function related
to mitochondrial energy metabolism include several mito-
chondrial translocases (the genomic neighbor of the APOE
gene  TOMM40  [58] and the genes translocase of inner
mitochondrial membrane (TIMM) 13 and 44) and mitochon-
drial enzymes and complex subunits (branched-chain amino
acid transferase [58] and electron transfer flavoprotein sub-
unit β).
Of relevance to cancer, several cell cycle regulating genes
were found, such as G1/S-specific cyclin E [61], p19INK4d [58],
prostate tumor overexpressed gene, serine protease hepsin
[57] and those encoding the serine/threonine kinases associ-
ated with cell cycle regulation, p21-activated kinase 4 (PAK4)
and homeodomain-interacting protein kinase 4. In addition,
the prostate tumor marker kallikrein-3 [62] and several other
kallikrein gene family members were detected. Kallikreins
represent one gene family that likely arose by duplications on
chromosome 19; other such families include zinc finger pro-
teins, of which several also passed the filter and many are
detected on microarrays.
Other physiological roles that have been more recently stud-
ied in connection with PPARs include regulation of immune
reactions and muscle target genes. A large group of predicted
genes has functions in the immune system, such as the genes
killer cell immunoglobulin-like receptor 2DL4 [8], natural
killer cell protein 7 and bone marrow stromal antigen 2.
Putative muscle targets include the genes myotonic dystro-
phy protein kinase and tropomyosin α4-chain [8]. Interest-
ingly, in connection with effects on the circulatory system,
regulation of the lysophosphatidic acid (LPA) receptor gene
Edg-4 [58,63] has been detected, and here we predict two
other family members, Edg-6 and Edg-8, to also be regulated.
LPA leads to contraction of vessels, which is also achieved by
renin protein. Interestingly, among the genes detected is
chicken ovalbumin upstream promoter transcription factor
(COUP-TF) γ, which codes for a NR that is known to regulate
renin expression [64].
Validation of PPAR target genes on human 
chromosome 19
From these lists, the six human genes CYP4F8,  LASS1,
COUP-TFγ, PAK4, SLC27A5 and TIMM13 were selected for
real-time PCR evaluation of their response to the PPARα lig-
and GW7647 in HepG2 cells (Figure 9a). All these genes con-
tain at least one strong and one medium PPRE predicted to
bind PPARα. The genes COUP-TFγ, PAK4 and TIMM13 also
showed enrichment in mouse (for CYP4F8, no 1:1 ortholog
prediction exists). After 2 hours of treatment with ligand, all
6 genes showed a significant (between 1.8- and 4.2-fold) up-
regulation of their mRNA (Figure 9a). For a more detailed
analysis we selected the LASS1 gene. The in silico analysis of
the gene suggested four non-conserved PPREs, of which the
two strong REs in close vicinity (region 2) are the best candi-
dates for forming the PPAR-responsive region of the LASS1
gene (Figure 9b). Functional analysis of three genomic
regions in reporter gene assays in HepG2 cells indicated for
region 2 a significant up-regulation by PPARγ and PPARβ/δ
ligands and an even more prominent basal activity for the
PPARα agonist (Figure 9c). The two other regions did not
show a significant response to PPAR over-expression or
ligand treatment. ChIP assays in HepG2 cells confirmed this
result (Figure 9d). Treatment with GW7647 induced signifi-
cant binding of PPARα, RXRα and pPol II to region 2, but not
to regions 1 and 3. This suggests that the two strong PPREs in
region 2 mediate the response of the LASS1 gene to PPAR
ligands.
Taken together, the in silico screening of 956 genes from
human chromosome 19 suggest that 12.1% of them have two
or more PPREs in both the human and mouse orthologs; and
SOM analysis of established primary PPAR target genes, clusters III and IV Figure 7 (see previous page)
SOM analysis of established primary PPAR target genes, clusters III and IV. The genes were sorted by SOM analysis with respect to overall PPRE pattern 
similarity and their evolutionary conservation into (a) cluster III and (b) cluster IV. For more details, see the Figure 6 legend.R147.18 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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Figure 8 (see legend on next page)
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8.7% of all genes from chromosome 19 even carry an assem-
bly of three or more PPREs. All six genes of this panel show
early responses in their mRNA expression levels to the
presence of a PPARα ligand. Using the LASS1 gene as an
example, we demonstrated that the most likely region, con-
taining two PPREs, is functional and recruits PPARα and
RXRα and is associated with pPol II.
Discussion
The identification of genes showing a primary response to
PPARs and their ligands, the PPAR regulome, can be used for
prediction of their therapeutic potential as well as their possi-
ble side effects. In this study, we present a method that incor-
porates both experimental- and informatics-derived evidence
to arrive at a more reliable prediction of PPAR target genes.
We provide here DNA-binding data for all three PPAR sub-
types to a large panel of natural and synthetic DR1-type REs.
We describe a PPRE classifier and test it together with two
matrix methods based on the binding data to detect and pre-
dict the in vitro binding strength of PPAR-RXR heterodimers
to their REs. Although all methods provide relatively good
discrimination of sequences that bind PPARs from those that
do not, the classifier also retained a close correlation between
the prediction and the experimental binding strength and was
chosen for the further assessment of PPAR target genes.
Previously, scoring of putative PPREs has been based on an
alignment of a number of natural PPREs that were used to
create PSWMs as opposed to the PSWM presented here,
which uses experimentally verified strong or medium PPREs
from our dataset. These are the basis for commonly used pro-
grams for in silico screening of NR REs, such as ConSite and
JASPAR. However, longer binding sites, such as those of NRs
composed of two half sites, could be especially challenging for
weight matrix approaches because they create mathematical
scores over the whole length of the binding sequence.
Therefore, they may be prone to overcompensate for nucleo-
tides that are totally unfavorable for binding at one position
with scores from other positions.
Another assumption underlining the matrix scores is the
base-independence assumption. This was recently challenged
by a study that collected a large dataset of affinity data for the
basic helix-loop-helix transcription factor family [65]. As the
number of consensus variations was increased, predictions
based on an affinity matrix that was created on the basis of
single nucleotide variation data correlated poorly with exper-
imental binding of multiple variation data. However, the util-
ity of more complex models incorporating the base-
dependence assumption has been challenged in the context of
other transcription factors [66]. Although the data we present
here seem to be in line with the observation that the correla-
tion of matrix scores with binding strength is not obvious,
systematic di- or trinucleotide screening data would be
needed to challenge this idea. The usefulness of the matrix
methods for the detection of binding sites is widely acknowl-
edged and the two matrices presented here perform well in
this regard.
Since our classifier performed well in all tests, it was chosen
for binding strength prediction. As shown for the example of
the REs of the human UCP3 gene, the in silico prediction of
PPAR-RXR heterodimer binding strength fits well with their
experimentally determined binding. Due to the large number
of possible variations, we consider a ± 15% interval for a
match between prediction and true binding strength as suffi-
cient to evaluate the binding site composition of target genes.
Moreover, the classifier is also sensitive, since optimal per-
formance was already reached with a threshold for PPRE
binding of 3% relative to the consensus.
We extended our in silico screening to a distance of 10 kB
upstream and downstream of the TSS. This limit is above the
restrictions of genome-wide promoter screens for transcrip-
tion factor binding sites [15] and also acknowledges the rather
recent understanding that regulatory sequences are
symmetrically located around the TSS [67]. Our experimental
analysis of 23 genomic regions of 8 validated PPAR target
genes, which together contain 30 putative PPREs, indicated
that the majority of them are functional (17 regions in
HEK293 cells). Moreover, in living cells we detected for 12
regions a significant, mostly PPAR ligand-dependent associa-
tion of PPARα, RXRα and pPol II. Prevalence of strong
PPREs seems to be a common feature among direct PPAR tar-
get genes, since all eight investigated genes contain at least
one functional region, each carrying at least one strong PPRE.
Moreover, based on this set of functional regions, we could
not detect any positional bias towards the TSS. This agrees
with other data concerning the positioning of NRs relative to
the TSS [15]. For example, for genes such as human ACOX1
and RVRα, where for historical reasons PPREs rather close to
the TSS were reported, we show that the respective PPRE-
containing regions were not functional. Instead, we suggest
for these two genes (and also for a couple of others) a number
of alternative PPAR-responding regions more distant from
the TSS or downstream of it. For the UCP3 gene, for which no
PPRE had so far been reported, we show three PPAR-
Conservation patterns across multiple species Figure 8 (see previous page)
Conservation patterns across multiple species. The genes ACOX1 and ANGPLT4 from chicken, chimpanzee, dog, rat and zebrafish were also analyzed. 
Putative PPREs (red boxes, no conservation; orange boxes, within conserved area; yellow boxes, conserved in human; pink boxes, conserved in mouse) 
were identified by in silico screening of the genomic sequences. For each of the predicted PPREs, the calculated binding strengths of PPARα (green), PPARγ 
(dark blue) and PPARβ/δ (light blue) in reference to a consensus DR1-type PPRE are represented by column height. All putative PPRE sequences are 
available on request.R147.20 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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Table 4
Predicted PPAR target genes in human chromosome 19
Ensembl ID (human) Gene name Ensembl ID (mouse)
ENSG00000004776 Heat-shock protein beta-6 ENSMUSG00000036854
ENSG00000004777 TC10/CDC42 GTPase-activating protein ENSMUSG00000036882
ENSG00000005007 Regulator of nonsense transcripts 1 ENSMUSG00000058301
ENSG00000010310 Gastric inhibitory peptide receptor ENSMUSG00000030406
ENSG00000032444 Neuropathy target esterase ENSMUSG00000004565
ENSG00000039987 Bestrophin-2 ENSMUSG00000052819
ENSG00000060566 cAMP responsive element binding protein 3-like 3 ENSMUSG00000035041
ENSG00000063176 Sphingosine kinase 2 ENSMUSG00000057342
ENSG00000063241 Isochorismatase domain containing 2 ENSMUSG00000052605
ENSG00000064547 Lysophosphatidic acid receptor Edg-4 ENSMUSG00000031861
ENSG00000072954 Transmembrane protein 38A ENSMUSG00000031791
ENSG00000072958 AP-1 complex subunit mu-1 ENSMUSG00000003309
ENSG00000076944 Syntaxin binding protein 2 ENSMUSG00000004626
ENSG00000077348 Exosome complex exonuclease RRP46 ENSMUSG00000061286
ENSG00000079435 Lipase, hormone sensitive ENSMUSG00000053714
ENSG00000080031 Protein tyrosine phosphatase, receptor type, H precursor ENSMUSG00000035429
ENSG00000080511 Retinol dehydrogenase 8 ENSMUSG00000053773
ENSG00000083807 SLC27A5 ENSMUSG00000030382
ENSG00000083838 Zinc finger protein 446 ENSMUSG00000033961
ENSG00000089327 FXYD domain-containing ion transport regulator 5 precursor ENSMUSG00000009687
ENSG00000089639 GEM-interacting protein ENSMUSG00000036246
ENSG00000099203 Transmembrane emp24 domain-containing protein 1 precursor ENSMUSG00000032180
ENSG00000099308 Microtubule-associated serine/threonine-protein kinase 3 ENSMUSG00000031833
ENSG00000099331 Myosin-9B ENSMUSG00000004677
ENSG00000099617 Ephrin-A2 precursor ENSMUSG00000003070
ENSG00000099622 Cold-inducible RNA-binding protein ENSMUSG00000045193
ENSG00000099800 TIMM13 ENSMUSG00000020219
ENSG00000104826 Lutropin β chain precursor ENSMUSG00000038194
ENSG00000104859 Splicing factor arginine/serine rich 16 ENSMUSG00000061028
ENSG00000104863 LIN-7 homolog B ENSMUSG00000003872
ENSG00000104870 IgG receptor FcRn large subunit p51 precursor ENSMUSG00000003420
ENSG00000104918 Resistin ENSMUSG00000012705
ENSG00000104936 Myotonin-protein kinase ENSMUSG00000030409
ENSG00000104946 TBC1 domain family member 17 ENSMUSG00000038520
ENSG00000104960 Prostate tumor overexpressed gene 1 ENSMUSG00000038502
ENSG00000104980 Import inner membrane translocase subunit TIM44 ENSMUSG00000002949
ENSG00000105066 Flt3-interacting zinc finger protein 1 ENSMUSG00000061374
ENSG00000105173 G1/S-specific cyclin-E1 ENSMUSG00000002068
ENSG00000105204 Dual specificity tyrosine-phosphorylation-regulated kinase 1B ENSMUSG00000002409
ENSG00000105287 Serine/threonine-protein kinase D2 ENSMUSG00000041187
ENSG00000105289 Tight junction protein ZO-3 ENSMUSG00000034917
ENSG00000105364 Mitochondrial 39S ribosomal protein L4 ENSMUSG00000003299
ENSG00000105374 Natural killer cell protein 7 ENSMUSG00000004612
ENSG00000105379 Electron transfer flavoprotein subunit β  ENSMUSG00000004610
ENSG00000105398 SULT2A1 ENSMUSG00000074375
ENSG00000105447 Glutamate-rich WD repeat-containing protein 1 ENSMUSG00000053801
ENSG00000105467 Synaptogyrin-4 ENSMUSG00000040231
ENSG00000105516 D site-binding protein ENSMUSG00000059824http://genomebiology.com/2007/8/7/R147 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. R147.21
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ENSG00000105552 Branched-chain-amino-acid aminotransferase ENSMUSG00000030826
ENSG00000105664 Cartilage oligomeric matrix protein precursor ENSMUSG00000031849
ENSG00000105701 38 kDa FK506-binding protein homolog ENSMUSG00000019428
ENSG00000105707 Serine protease hepsin ENSMUSG00000001249
ENSG00000108106 Ubiquitin-conjugating enzyme E2 S ENSMUSG00000060860
ENSG00000118046 Serine/threonine-protein kinase 11 ENSMUSG00000003068
ENSG00000119574 Zinc finger protein 499 ENSMUSG00000049600
ENSG00000123154 Mitogen-activated protein kinase organizer 1 ENSMUSG00000005150
ENSG00000125910 Sphingosine 1-phosphate receptor Edg-6 ENSMUSG00000044199
ENSG00000125912 Nicalin precursor ENSMUSG00000020238
ENSG00000126246 Transmembrane protein 149 ENSMUSG00000036826
ENSG00000126247 Calpain small subunit 1 ENSMUSG00000001794
ENSG00000127526 SLC35E1 ENSMUSG00000019731
ENSG00000129355 Cyclin-dependent kinase 4 inhibitor D ENSMUSG00000066860
ENSG00000129451 Kallikrein-10 precursor ENSMUSG00000030693
ENSG00000129455 Kallikrein-9 precursor ENSMUSG00000047884
ENSG00000130165 Transcription elongation factor 1 homolog ENSMUSG00000013822
ENSG00000130288 NADH dehydrogenase 1 α subcomplex subunit 13 ENSMUSG00000036199
ENSG00000130300 Plasmalemma vesicle-associated protein ENSMUSG00000034845
ENSG00000130303 Bone marrow stromal antigen 2 ENSMUSG00000046718
ENSG00000130402 α-actinin-4 ENSMUSG00000054808
ENSG00000130520 U6 snRNA-associated Sm-like protein LSm4 ENSMUSG00000031848
ENSG00000130522 Transcription factor jun-D ENSMUSG00000071076
ENSG00000130669 PAK 4 ENSMUSG00000030602
ENSG00000130687 AlkB, alkylation repair homolog 6 isoform 2 ENSMUSG00000042831
ENSG00000130755 Glia maturation factor, gamma ENSMUSG00000060791
ENSG00000130818 Zinc finger protein 426 ENSMUSG00000059475
ENSG00000130881 Low-density lipoprotein receptor-related protein 3 precursor ENSMUSG00000001802
ENSG00000131398 Potassium voltage-gated channel subfamily C member 3 ENSMUSG00000062785
ENSG00000132024 Coiled-coil and C2 domain-containing protein 1A ENSMUSG00000036686
ENSG00000133246 PML-RARα-regulated adaptor molecule 1 ENSMUSG00000032739
ENSG00000141837 Voltage-dependent P/Q-type calcium channel subunit α-1A ENSMUSG00000034656
ENSG00000142009 Pyroglutamyl-peptidase I ENSMUSG00000056204
ENSG00000142290 FXYD domain-containing ion transport regulator 7 ENSMUSG00000036578
ENSG00000142513 Testicular acid phosphatase isoform β precursor ENSMUSG00000012777
ENSG00000142538 Tuberoinfundibular peptide of 39 residues precursor ENSMUSG00000038300
ENSG00000142539 Spi-B transcription factor ENSMUSG00000008193
ENSG00000160113 COUP-TFγ  ENSMUSG00000002393
ENSG00000160318 Claudin domain containing 2 ENSMUSG00000038973
ENSG00000160396 Homeodomain-interacting protein kinase 4 ENSMUSG00000040424
ENSG00000161249 Dermokine isoform β ENSMUSG00000060962
ENSG00000161558 Transmembrane protein 143 ENSMUSG00000002781
ENSG00000161677 Josephin-2 ENSMUSG00000038695
ENSG00000167460 Tropomyosin α-4 chain ENSMUSG00000031799
ENSG00000167470 Midnolin ENSMUSG00000035621
ENSG00000167578 Ras-related protein Rab-4B ENSMUSG00000053291
ENSG00000167754 Kallikrein-5 precursor ENSMUSG00000074155
ENSG00000167757 Kallikrein-11 precursor ENSMUSG00000067616
ENSG00000167772 ANGPLT4 ENSMUSG00000002289
ENSG00000167775 CD320 antigen precursor ENSMUSG00000002308
Table 4 (Continued)
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responding regions containing strong and medium strength
PPREs. In conclusion, our binding site strength prediction
scheme allows us to identify novel, functional PPREs from
known PPAR targets that are experimentally verifiable.
Meta-analysis of 38 established PPAR responding genes indi-
cated that the most convincing PPAR targets contain two or
more strong (or at least medium) PPREs in both the human
and mouse orthologs. Our detailed knowledge of the DNA-
binding preferences of PPARs combined with insights from
the meta-analysis of a large number of PPAR targets gave us
the advantage of being able to detect characteristics of target
genes that were ignored before. We investigated genomic var-
iables, such as PPRE location relative to the TSS and their
evolutionary conservation, in an unbiased way. The identifi-
cation of, in total, 13 subclusters in the set of established
PPAR target genes suggests that evolutionary constraints to
maintain responsiveness do not translate to the preservation
of an identical PPRE pattern; instead, the appearance and fix-
ation of novel sites adds flexibility. In effect, evolution has
chosen a number of different strategies to acquire and main-
tain the responsiveness of genes to PPARs. Based on the set of
known targets, this appears to manifest itself as an enrich-
ment of strong binding sites. Furthermore, as suggested by
our experimental evaluation of PPREs, more than one of
these sites may be functional for any given time. By tracking
this enrichment and turnover of binding sites from multiple
species, our in silico screening approach has, compared to
other methods, an increased chance to detect eventually all
PPAR target genes in a chromosome or even a whole genome.
ENSG00000168813 Zinc finger protein 507 ENSMUSG00000044452
ENSG00000171236 Leucine-rich α-2-glycoprotein precursor ENSMUSG00000037095
ENSG00000171443 Zinc finger protein 524 ENSMUSG00000051184
ENSG00000171570 Egl nine homolog 2 ENSMUSG00000058709
ENSG00000174521 Tetratricopeptide repeat domain 9B ENSMUSG00000007944
ENSG00000174562 Kallikrein-15 precursor ENSMUSG00000055193
ENSG00000176531 Pleckstrin homology-like domain family B member 3 ENSMUSG00000061511
ENSG00000178093 Testis-specific serine/threonine-protein kinase 6 ENSMUSG00000047654
ENSG00000180448 Minor histocompatibility antigen HA-1 ENSMUSG00000035697
ENSG00000180739 Sphingosine 1-phosphate receptor Edg-8 ENSMUSG00000045087
ENSG00000185761 Thrombospondin, type I, domain containing 6 ENSMUSG00000043822
ENSG00000185800 Dystrophia myotonica WD repeat-containing protein ENSMUSG00000030410
ENSG00000186474 Kallikrein-12 precursor ENSMUSG00000044430
ENSG00000196867 Zinc finger protein 28 homolog ENSMUSG00000062861
ENSG00000197050 Zinc finger protein 420 ENSMUSG00000058402
ENSG00000198356 Arsenical pump-driving ATPase ENSMUSG00000052456
ENSG00000204673 AKT1 substrate 1 ENSMUSG00000011096
ENSG00000205155 Gamma-secretase subunit PEN-2 ENSMUSG00000036835
All 956 genes of human chromosome 19 that have known mouse orthologs were screened in silico for strong and medium PPREs within 10 kB 
upstream and downstream of the gene's annotated TSS. All putative PPRE sequences are available on request. The 116 genes that carry, in both 
species, a strong PPRE or two or more medium PPREs, or a medium PPRE within 500 bp upstream of the TSS are listed. The 50 genes that pass the 
even more stringent criterion of three PPREs, including one strong, are highlighted in bold.
Table 4 (Continued)
Predicted PPAR target genes in human chromosome 19
Validation of novel PPAR target genes on human chromosome 19 Figure 9 (see following page)
Validation of novel PPAR target genes on human chromosome 19. (a) Real-time quantitative PCR was used to determine the inducibility of the mRNA 
expression of the indicated eight PPAR target genes, relative to the control gene RPLP0, in HepG2 cells. The cells were stimulated for 2, 4 and 6 h with 100 
nM GW7647. (b) An overview of the genomic organization of the human LASS1 gene; 10 kB upstream and downstream of the TSS are shown. Putative 
REs were identified by in silico screening and the calculated binding strengths of the PPAR subtypes are represented by columns in reference to a consensus 
DR1-type PPRE. All putative PPRE sequences are available on request. (c) Reporter gene assays were performed with extracts from HepG2 cells that 
were transiently transfected with luciferase reporter constructs containing genomic regions of the LASS1 gene together with empty expression vector 
(endogenous PPAR) or the indicated expression vectors for PPARα, PPARγ and PPARβ/δ. Cells were then treated for 16 h with solvent or PPAR subtype-
specific ligands. Relative luciferase activity was determined and normalized to the activity of empty cloning vector control co-transfected with empty 
expression vector. (d) Chromatin was extracted from HepG2 cells that had been treated with solvent or for 120 minutes with 100 nM GW7647. The 
association of PPARα, RXRα and pPol II was monitored by ChIP assays with respective antibodies on three genomic regions of the LASS1 gene. Real-time 
quantitative PCR was performed on chromatin templates and fold change of antibody-precipitated template in relation to IgG-precipitated specificity 
control template was calculated. Columns in (a, c, d) represent means of at least three experiments and bars indicate standard deviations. Two-tailed 
Student's t-tests were performed to determine the significance (*p < 0.05, **p < 0.01).http://genomebiology.com/2007/8/7/R147 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. R147.23
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2007, 8:R147
Figure 9 (see legend on previous page)
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As an example, we screened human chromosome 19 for
PPREs and predicted PPAR target genes. Among the 956
genes of human chromosome 19 for which we could identify
mouse orthologs, we predicted 116 genes (12.1%) from both
species to be PPAR target genes by tracking the appearance of
strong sites, or enrichment of medium/strong sites in both
species. This approach has the ability to detect targets with
divergent PPRE composition. Such an analysis will be even be
more powerful with the incorporation of additional genomes,
in particular in the detection of PPAR targets that differ
between human and mouse. By using only one species we lim-
ited our search to a more stringent screening for genes with
both enrichment of PPREs (three or more PPREs) and a
strong PPRE. This suggested that 118 of the 1,445 genes of
human chromosome 19 (8.2%) are PPAR targets. These genes
comprise interesting candidates representing physiological
functions connected to PPAR. For a group of six genes that
are representative for the predicted PPAR targets, all were
experimentally proven to respond to PPAR ligands. This sug-
gests that selectivity is also high when assessed in proper
physiological contexts (tissues). We plan to extend our analy-
sis beyond chromosome 19 to the whole human genome with
the incorporation of more species as soon their complete
sequences become available. Taking both whole chromosome
19 in silico screening trials together and extrapolating the
results to the whole human genome, we suggest that approx-
imately 10% of all human genes (an estimate of 2,000 to
2,500 genes) have the potential to be directly regulated by
PPARs. Incidentally, this fits with experimental data regard-
ing PPARα targets [13].
From the six representative genes of human chromosome 19
we selected the LASS1 gene for more detailed analysis. The in
silico screening of this gene suggested that it has four REs in
three regions. Of these, region 2 is the most obvious PPAR
regulatory region, since it contains a strong PPRE in close
vicinity to a medium PPRE. In fact, reporter gene and ChIP
assays confirmed this prediction in reference to non-func-
tional regions of the same gene. Together with the results
observed with the UCP3 gene, this suggests that our method
is a reliable approach not only to predict primary PPAR target
genes on a genomic scale but also to identify in silico regula-
tory regions with functional PPREs for each individual gene.
Conclusion
We present here the development of an experiment-based
informatics method for more reliable prediction of PPAR tar-
get genes on the whole genome level and important insights
into the relationship of different genomic variables to PPRE
functionality and the turnover of their binding sites during
evolution. This approach and the underlying concepts can
also be applied to other members of the NR superfamily and
explored for use with all DNA-binding transcription factors
for which sufficient reliable DNA-binding data are available.
Materials and methods
In silico screening of putative PPREs using a PPRE 
classifier
Data for the in vitro binding of the three PPAR subtypes to 39
single nucleotide variations of a consensus PPRE [18] were
sorted into classes I, II and III (Table 1). To address binding
to multiple variations, a total of 136 DR1-type RE sequences
were tested for the in vitro binding of PPAR-RXR heterodim-
ers and then used to calculate the average binding strength of
the three PPAR subtypes in each of the categories 1/0/0, 0/1/
0, 2/0/0, 3/0/0, 1/1/0, 0/0/1, 0/2/0, 2/1/0, 1/0/1, 3/1/0 and
4/0/0 (Figure 1), where the numbers indicate the number of
variations for the classes I, II and III, respectively. Other
combinations resulted in less than 1% average binding (Addi-
tional data file 1) and were not considered for the PPRE
search. Genomic sequences for human and mouse ortholo-
gous genes spanning a 10 kB distance to their respective TSSs
were extracted from the Ensembl database (release 40, April
2006) and screened for DR1-type REs using in-house
software named RESearch (source code and templates for
searching for medium/strong PPREs are available upon
request) [68]. A list of all possible PPREs belonging to
medium and strong PPRE categories are described in tem-
plate files that the program uses to annotate the sequence
files. The naming of results corresponds to the category where
the RE is found. The PPAR subtype-specific binding strength
was predicted based on data from Figure 1. The conservation
of the putative PPREs between human and mouse were eval-
uated using the Vertebrate Multiz Alignment and Conserva-
tion track available from the UCSC genome browser (NCBI
releases for human and mouse genomes, hg18 and mm8, Feb-
ruary 2006) [69]. The ANGPLT4  and  ACOX1  genes were
extracted from Ensembl for chicken (2.1, May 2006), chim-
panzee (PanTro 2.1, March 2006), dog (CanFam 2.0, May
2005), rat (RGSC 3.4, November 2004) and zebrafish (Zv6,
March 2006). Human chromosome 19 and its syntenic mouse
regions were extracted from Ensembl release 41 and screened
for putative PPREs of strong or medium predicted binding
strength at a distance of up to 10 kB from each TSS. The
Ensembl ortholog prediction was used to match the respec-
tive human and mouse genes.
Construction of a PSWM and a PSAM
The PPARγ binding data were used to construct the matrices.
For the weight matrix all medium and strong PPREs that con-
tain multiple variations were included. This set of 20
sequences was used to calculate frequencies of each base-
pair, which were then divided by the background frequency
(assumed equal for all base-pairs). A pseudocount of 0.01 was
introduced to the calculation to represent unobserved base-
pairs. The values were converted to matrix weights by taking
the natural logarithm of the corrected frequency values. The
single nucleotide variation data were used to construct the
affinity matrix. The binding strength of the different nucleo-
tides (values between 0 and 1) in a given position was con-
verted to a matrix value by setting each column sum equal tohttp://genomebiology.com/2007/8/7/R147 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. R147.25
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1 .  T o  c o r r e l a t e  m a t r i x  s c o r e  w i t h  e x p e r i m e n t a l  b i n d i n g
strength, the equations of the lines fitted to the single nucleo-
tide variation data (Additional data file 3) were used to con-
vert a matrix score to a binding prediction.
Comparison of in silico methods
Two sets of rules were used to define true positives (TPs),
false positives (FPs), true negatives (TNs) and false negatives
(FNs). To discriminate sequences that bind PPARs from
those that do not, the following definitions were used: TP =
the score is over the threshold and the sequence binds PPAR
(in the case where the classifier score = average); TN = the
score is below the threshold and the sequence does not bind
PPAR; FP = the score is over the threshold but the sequence
does not bind PPAR; FN = the score is below the threshold but
the sequence binds PPAR. To compare if a prediction/score
given by the method correlated with binding strength, the fol-
lowing definitions were used: TP = the prediction matches
experimental binding with 15% of the consensus as the toler-
ance limit (5% for sequences predicted to bind less than 15%)
and the sequence binds PPREs; TN = the observed binding is
less than the prediction threshold (optimal thresholds were
3% for classifier, 30% or 0.0000015 for PSAM and 20% or 4.7
for the PSWM); FP = the observed binding is lower than pre-
dicted and outside the 15% tolerance interval for a match; FN
= the observed binding is higher than predicted and outside
the 15% tolerance interval for a match. These values were
used to calculate the true positive and false positive rates:
TPR = TP/P = TP/(TP + FN); FPR = FP/N = FP/(FP + TN).
The performance of the methods was compared by calculat-
ing predictions for the experimental data from Figure 1 and
Additional data file 1 using the different methods. This data-
set contains a well-defined true negative set (all non-binding
sequences representing approximately 30% of data) and a
well-defined true positive set.
Cell culture
The human embryonal kidney cell line HEK293 and the
human hepatocarcinoma cell line HepG2 were cultured in
Dulbecco's modified Eagle's medium (DMEM) containing
10% fetal bovine serum (FBS), 2 mM L-glutamine, 0.1 mg/ml
streptomycin and 100 units/ml penicillin in a humidified 95%
air/5% CO2 incubator. Before use, the FBS was stripped of
lipophilic compounds, such as endogenous NR ligands, by
stirring it with 5% activated charcoal (Sigma-Aldrich, St
Louis, MO, USA) for 3 h at room temperature. Charcoal was
then removed by centrifugation and sterile filtration. Prior to
mRNA or chromatin extraction, cells were grown overnight in
p h e n o l  r e d - f r e e  D M E M  s u p p l e m e n t e d  w i t h  5 %  c h a r c o a l -
stripped FBS to reach a density of 50-60% confluency. Cells
were then treated with either solvent (DMSO, 0.1% final con-
centration) or 100 nM of the PPARα agonist GW7647
(2-(4-(2-(1-cyclohexanebutyl-3-cyclohexylureido)ethyl)phe-
nylthio)-2-methylpropionic acid), 100 nM of the PPARγ ago-
nist rosiglitazone(5-((4-(2-(methyl-2-pyridinylamino)
ethoxy)phenyl)methyl)-2,4-thiazolidinedione) or 100 nM of
the PPARβ/δ agonist GW501516 (2-methyl-4-((4-methyl-2-
(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)-methylsulfa-
nyl)phenoxy-acetic acid). GW7647 and GW501516 were pur-
chased from Alexis Biochemicals (San Diego, CA, USA), while
rosiglitazone was kindly provided by Dr Mogens Madsen (Leo
Pharma, Ballerup, Denmark). The ligands were dissolved and
diluted in DMSO.
RNA extraction and quantitative real-time PCR
Total RNA was extracted using the Mini RNA Isolation II kit
(ZymoResearch, HiSS Diagnostics, Freiburg, Germany).
The RNA was purified and eluted according to the manufac-
turer's instructions (ZymoResearch). cDNA synthesis was
performed for 1 h at 37°C using 1 μg of total RNA as a tem-
plate, 100 pmol of oligo(dT15) primer and 40 units of reverse
transcriptase (Fermentas, Vilnius, Lithuania) in a 40 μl vol-
ume. Subsequently, the cDNA was diluted 1:10 with H2O.
Real-time quantitative PCR was performed in an IQcycler
(BioRad, Hercules, CA, USA) using the dye SybrGreen I
(Molecular Probes, Leiden, The Netherlands). Per reaction,
4  μl cDNA, 1 U FastStart Taq polymerase (Roche, Man-
nheim, Germany) and 2 mM MgCl2 were used. The PCR
cycling conditions were: 45 cycles of 30 s at 95°C, 30 s at
60°C and 25 s at 72°C. The sequences of the gene-specific
primer pairs for the PPAR target genes and the internal con-
trol gene acidic riboprotein P0 (RPLP0) are listed in Table
5. PCR product quality was monitored using post-PCR melt
curve analysis. The fold inductions were calculated using 2-
(ΔΔCt), where ΔΔCt is the ΔCt(PPAR ligand) - ΔCt(DMSO), ΔCt is
Ct(target gene) - Ct(RPLP0) and Ct is the cycle at which the thresh-
old is crossed.
DNA constructs
Full-length cDNAs for human PPARα [70], human PPARγ
[71], human PPARβ/δ [72] and human RXRα [73] were sub-
cloned into the T7/SV40 promoter-driven pSG5 expression
vector (Stratagene, La Jolla, CA, USA). The same constructs
were used for both T7 RNA polymerase-driven in vitro tran-
scription/translation of the respective cDNAs and for viral
promoter-driven over-expression in mammalian cells.
Selected genomic regions of PPAR target genes were cloned
by PCR from human genomic DNA (for primers see Table 2)
and fused with the thymidine kinase promoter driving the
firefly luciferase reporter gene.
Clustering of gene data using SOMs
PPAR target genes were clustered using Visual Data software
(Visipoint OY, Kuopio, Finland), which is based on SOMs.
These are artificial neural network algorithms in the unsuper-
vised learning category that can visualize and interpret large
high-dimensional datasets [74]. The map consists of a regular
grid of processing units, so-called 'neurons', which are organ-
ized hierarchically in a pyramid-like fashion in several layers.
Four adjacent neurons of the best matching unit form the
neighborhood that gets updated. The lower levels of the mapR147.26 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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provide a coarse mapping of the data, while fine structures
and clusters emerge when more neurons are used. For the
best visualization, the SOM vectors were used as an input for
the Sammon algorithm. The input dataset of the SOM con-
sisted of six variables (shown according to final SOM cluster-
ing in Additional data file 5). The variables BSH and BSM
represent the sum of predicted binding strength of n putative
medium or strong PPREs (Σbsn, bsi = max{bsPPARα, bsPPARγ,
bsPPARβ/δ}) found within the 20 kB of the analyzed region of
each gene in human (H) and mouse (M), respectively. The
remaining values indicate the number of conserved strong/
medium (CS) or weak (CW) PPREs in human and mouse.
Prior to SOM initialization the BS variables were scaled
between 0 and 1 and the maximal resolution was set to 256.
Finally, a Sammon's mapping algorithm (Visipoint OY) was
applied to visualize the clustered groups in n-dimensional
space in two dimensions. For this analysis the human and
mouse sequences were treated as independent sequences.
This may result in overestimation of conserved pairs; how-
ever, the evolutionary distance between the species is, in gen-
eral, considered sufficient to offer useful information about
conservation patterns.
Gelshift assay
In vitro translated PPAR subtype and RXRα proteins were
generated by coupled in vitro transcription/translation using
their respective pSG5-based full-length cDNA expression
constructs and rabbit reticulocyte lysate as recommended by
the supplier (Promega, Madison, WI, USA). Protein batches
were quantified by test-translations in the presence of [35S]-
methionine. Gelshift assays were performed with 10 ng of the
appropriate in vitro translated proteins. The proteins were
incubated for 15 minutes in a total volume of 20 μl of binding
buffer (150 mM KCl, 1 mM dithiothreitol, 25 ng/μl herring
sperm DNA, 5% glycerol, 10 mM Hepes, pH 7.9). Constant
amounts (1 ng) of [32P]-labeled double-stranded oligonucle-
otides (50,000 cpm) containing one copy of the respective
REs were then added and incubation was continued for 20
minutes at room temperature. Protein-DNA complexes were
resolved by electrophoresis through 8% non-denaturing poly-
Table 5
PCR primer pairs for quantitative real-time PCR
Gene Primer pairs (5'-3') Product size (bp)
ACOX1 GTATGGAATCAGTCAGAACGC
CTTGTAAGATTCGTGGACCTC
261
ANGPLT4 GAGCCTCTCTGGAGGCTGGTG
CAGTCGTGGTCTTCTTCTCTG
334
APOC3 CATGCAGGGTTACATGAAGCAC
GTAGGAGAGCACTGAGAATAC
325
CPT1B TTCTGCCTTTACTTGGTCTCCA
GGGTCGAACATGCGGATCT
124
PPARa TGCTGTCTTCTGTGATGAAC
TCTGAGCACATGTACAATAC
268
CYP4F8 CATCTTCGCAATCCATCACAAC
GACCACCTTCATCTCTGCCATC
174
LASS1 CAGCTTGAGTTCACCAAGCTC
CACGATGTACAGGAACCAGTAG
266
NR2F6 GTGGCTTTCATGGACCAG
CAGCATGTCTCTGATCAGTG
344
PAK4 GAGCGACTCGATCCTGCTGAC
GACCAGATGTCTACCTCTG
173
RVRa AGGACCAGACAGTGATGTTC
CTTCTCGGAATGCATGTTGTTC
343
SLC27A5 CAGGTTGTGAGGGTAAGGTG
CATCAGTTTGAACGTGCTGGTG
169
SULT2A1 GATTATGTAGTGGACAAAGCAC
CAAGGAAGGGATCAGAGATG
296
UCP3 CACCTGCTCACTGACAACTTC
GTTACGAACATCACCACGTTC
247
TIMM13 CAGAGGATGACGGACAAGTG
GGTCACATGTTGGCTCGTTC
172
RPLP0 AGATGCAGCAGATCCGCAT
GTGGTGATACCTAAAGCCTG
318
PCR product sizes are indicated.http://genomebiology.com/2007/8/7/R147 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. R147.27
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acrylamide gels (mono- to bisacrylamide ratio 19:1) in 0.5 ×
TBE (45 mM Tris, 45 mM boric acid, 1 mM EDTA, pH 8.3) for
90 minutes at 200 V and quantified on a FLA-3000 reader
(Fuji, Tokyo, Japan) using ScienceLab99 software (Fuji).
ChIP assays
Nuclear proteins were cross-linked to genomic DNA by add-
ing formaldehyde for 5 minutes directly to the medium to a
final concentration of 1% at room temperature. Cross-linking
was stopped by adding glycine to a final concentration of
0.125 M and incubating for 5 minutes at room temperature on
a rocking platform. The medium was removed and the cells
were washed twice with ice-cold phosphate-buffered saline
(140 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM
Na2HPO4•2H2O). Cells were first collected by scraping into
ice-cold phosphate-buffered saline (PBS). After centrifuga-
tion the cell pellets were resuspended in lysis buffer (1% SDS,
10 mM EDTA, protease inhibitors (Roche), 50 mM Tris-HCl,
pH 8.1) and the lysates were sonicated to result in DNA frag-
ments of 300 to 1,000 bp in length. Cellular debris was
removed by centrifugation and the lysates were diluted 1:10 in
ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM NaCl, protease inhibitors, 16.7 mM Tris-HCl,
pH 8.1). The samples were centrifuged and the recovered
chromatin solutions were incubated with 5 μl of indicated
antibodies and 24 μl of sonicated salmon sperm (0.1 mg/ml)
to remove unspecific background overnight at 4°C with rota-
tion. The antibodies against PPARα (sc-9000), RXRα (sc-
553), phosphorylated RNA polymerase II (pPol II, sc-13583)
and control IgGs (sc-2027) were obtained from Santa Cruz
Biotechnologies (Heidelberg, Germany). The immuno-com-
plexes were collected by incubation with 60 μl of protein A-
agarose slurry (Upstate Biotechnology, Lake Placid, NY, USA)
for 1 h at 4°C with rotation. The beads were pelleted by cen-
trifugation for 1 minute at 4°C at 100 × g and washed
sequentially for 5 minutes by rotation with 1 ml of the follow-
ing buffers: low salt wash buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1), high
salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
500 mM NaCl, 20 mM Tris-HCl, pH 8.1) and LiCl wash buffer
(0.25 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1
mM EDTA, 10 mM Tris-HCl, pH 8.1). Finally, the beads were
washed twice with 1 ml of TE buffer (1 mM EDTA, 10 mM
Tris-HCl, pH 8.0). The immuno-complexes were then eluted
by adding 250 μl elution buffer (1% SDS, 100 mM NaHCO3)
and incubated for 15 minutes at room temperature with
rotation. After centrifugation, the supernatant was collected
and the elution was repeated. The supernatants were com-
bined. Subsequently, the cross-linking was reversed and
remaining proteins digested by adding proteinase K (final
concentration, 80 μg/ml; Fermentas) and incubating over-
night at 65°C. Genomic DNA fragments were recovered by
phenol-chloroform extraction, followed by a salt-ethanol pre-
cipitation and a final re-suspension in sterile H2O.
PCR of chromatin templates
For each of the PPRE-containing genomic regions of the
selected PPAR target genes, specific primer pairs were
designed (Table 2), optimized and controlled by running
PCR reactions with 25 ng of genomic DNA (input) as a tem-
plate. The Ct values obtained were used to define PCR con-
ditions for output samples. When running immuno-
precipitated DNA (output) as a template, the following
PCR profile was used: pre-incubation for 5 minutes at
95°C, (Ctinput + 10) cycles of 30 s at 95°C, 30 s at 60°C and
45 s at 72°C and one final incubation for 10 minutes at
72°C. PCR product quality was monitored using post-PCR
melt curve analysis. The fold inductions were calculated
using 2-(ΔCt), where ΔCt is Ct(specific antibody) - Ct(IgG control) and
Ct is the cycle at which the threshold is crossed. Relative
association levels were calculated using 2-(10-Ct(output-input)).
Transfection and reporter gene assay
HEK293 and HepG2 cells were seeded into 6-well plates (105
cells/ml) and grown overnight in phenol red-free DMEM sup-
plemented with 5% charcoal-stripped FBS. Polyethylene-
imine transfections were performed by incubating a reporter
plasmid and the expression vector for human PPARα, PPARγ
or PPARβ/δ (each 1 μg) with 50 μl of 150 mM NaCl for 15 min-
utes at room temperature. Simultaneously, 15 μg of polyeth-
yleneimine (Sigma-Aldrich) was incubated in 50 μl of 150
mM NaCl. The two solutions were then combined and incu-
bated for an additional 15 minutes at room temperature. After
dilution with 900 μl of phenol red-free DMEM, the mixture
was added to the cells. Phenol red-free DMEM (500 μl), sup-
plemented with 15% charcoal-stripped FBS and the ligands
were added 4 h after transfection. The cells were lysed 16 h
later using reporter gene lysis buffer (Roche). The constant
light signal luciferase reporter gene assay was performed as
recommended by the supplier (Perkin-Elmer, Groningen,
The Netherlands). Luciferase activities were normalized with
respect to protein concentration and induction factors were
calculated as the ratio of luciferase activity of ligand-stimu-
lated cells to that of solvent controls.
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a table of non-
binding DR1-type sequences. Additional data file 2 is a table
of ten training sets for classifier initializations. Additional
data file 3 is a figure comparing the PPRE classifier to matrix
methods. Additional data file 4 is a figure of expression pro-
filing of eight validated PPAR target genes in HEK293 and
HepG2 cells. Additional data file 5 is a table of the SOM input
data set. Additional data file 6 is a listing of further predicted
g e n e s  f r o m  c h r o m o s o m e  1 9  t h a t  h a v e  h i g h  e n r i c h m e n t  o f
PPREs in human only.
Additional data file 1 Non-binding DR1-type sequences Non-binding DR1-type sequences. Click here for file Additional data file 2 Ten training sets for classifier initializations Ten training sets for classifier initializations. Click here for file Additional data file 3 Comparison of the PPRE classifier to matrix methods Comparison of the PPRE classifier to matrix methods. Click here for file Additional data file 4 Expression profiling of eight validated PPAR target genes in  HEK293 and HepG2 cells Expression profiling of eight validated PPAR target genes in  HEK293 and HepG2 cells. Click here for file Additional data file 5 SOM input data set SOM input data set. Click here for file Additional data file 6 Further predicted genes from chromosome 19 that have high  enrichment of PPREs in human only Further predicted genes from chromosome 19 that have high  enrichment of PPREs in human only. Click here for fileR147.28 Genome Biology 2007,     Volume 8, Issue 7, Article R147       Heinäniemi et al. http://genomebiology.com/2007/8/7/R147
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